US20090191210A1 - Method for inhibiting tumor invasion or spreading in a subject - Google Patents
Method for inhibiting tumor invasion or spreading in a subject Download PDFInfo
- Publication number
- US20090191210A1 US20090191210A1 US11/891,680 US89168007A US2009191210A1 US 20090191210 A1 US20090191210 A1 US 20090191210A1 US 89168007 A US89168007 A US 89168007A US 2009191210 A1 US2009191210 A1 US 2009191210A1
- Authority
- US
- United States
- Prior art keywords
- rage
- tumor
- agent
- cells
- srage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 48
- 230000009400 cancer invasion Effects 0.000 title claims abstract description 22
- 206010064390 Tumour invasion Diseases 0.000 title claims abstract description 15
- 230000007480 spreading Effects 0.000 title claims abstract description 10
- 238000003892 spreading Methods 0.000 title claims abstract description 10
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 7
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 claims abstract description 203
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 claims abstract description 202
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 89
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 78
- 230000001413 cellular effect Effects 0.000 claims abstract description 37
- 206010027476 Metastases Diseases 0.000 claims abstract description 23
- 238000004113 cell culture Methods 0.000 claims abstract description 13
- 230000009401 metastasis Effects 0.000 claims abstract description 10
- 239000003937 drug carrier Substances 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 239000006143 cell culture medium Substances 0.000 claims abstract description 4
- 101710168537 High mobility group protein B1 Proteins 0.000 claims description 61
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 45
- 230000003993 interaction Effects 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 21
- 102000006495 integrins Human genes 0.000 claims description 15
- 108010044426 integrins Proteins 0.000 claims description 15
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 claims description 14
- 102000049409 human MOK Human genes 0.000 claims description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 11
- 238000012384 transportation and delivery Methods 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 8
- 238000007912 intraperitoneal administration Methods 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 210000002744 extracellular matrix Anatomy 0.000 claims description 5
- 239000002502 liposome Substances 0.000 claims description 5
- 108010085895 Laminin Proteins 0.000 claims description 4
- 102000007547 Laminin Human genes 0.000 claims description 4
- 239000000816 peptidomimetic Substances 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 102000000905 Cadherin Human genes 0.000 claims description 3
- 108050007957 Cadherin Proteins 0.000 claims description 3
- 102000016359 Fibronectins Human genes 0.000 claims description 3
- 108010067306 Fibronectins Proteins 0.000 claims description 3
- 238000007913 intrathecal administration Methods 0.000 claims description 3
- 238000010253 intravenous injection Methods 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 claims description 3
- 230000003442 weekly effect Effects 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 102000055207 HMGB1 Human genes 0.000 claims 3
- 210000004027 cell Anatomy 0.000 description 176
- 206010028980 Neoplasm Diseases 0.000 description 136
- 206010018338 Glioma Diseases 0.000 description 78
- 208000032612 Glial tumor Diseases 0.000 description 77
- 102100037907 High mobility group protein B1 Human genes 0.000 description 58
- 230000000694 effects Effects 0.000 description 48
- 241000699670 Mus sp. Species 0.000 description 35
- 230000014509 gene expression Effects 0.000 description 29
- 241001529936 Murinae Species 0.000 description 28
- 230000004614 tumor growth Effects 0.000 description 24
- 101100496572 Rattus norvegicus C6 gene Proteins 0.000 description 23
- 102000005962 receptors Human genes 0.000 description 21
- 108020003175 receptors Proteins 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 20
- 230000012010 growth Effects 0.000 description 19
- 241000699660 Mus musculus Species 0.000 description 18
- 102000007562 Serum Albumin Human genes 0.000 description 18
- 108010071390 Serum Albumin Proteins 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 18
- 238000011580 nude mouse model Methods 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 239000003446 ligand Substances 0.000 description 17
- 239000011159 matrix material Substances 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 15
- 238000012217 deletion Methods 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- 239000002202 Polyethylene glycol Substances 0.000 description 14
- 210000004072 lung Anatomy 0.000 description 14
- 229920001223 polyethylene glycol Polymers 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 230000009545 invasion Effects 0.000 description 13
- 238000013508 migration Methods 0.000 description 13
- 230000033115 angiogenesis Effects 0.000 description 12
- 230000005012 migration Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 238000003119 immunoblot Methods 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 230000001086 cytosolic effect Effects 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 206010061289 metastatic neoplasm Diseases 0.000 description 10
- 235000004279 alanine Nutrition 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 230000014511 neuron projection development Effects 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 8
- 108010088842 Fibrinolysin Proteins 0.000 description 8
- 230000004709 cell invasion Effects 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 108010082117 matrigel Proteins 0.000 description 8
- 229940012957 plasmin Drugs 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- 102000029816 Collagenase Human genes 0.000 description 7
- 108060005980 Collagenase Proteins 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 229960002424 collagenase Drugs 0.000 description 7
- 230000003292 diminished effect Effects 0.000 description 7
- 210000002889 endothelial cell Anatomy 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000001394 metastastic effect Effects 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000012292 cell migration Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 230000004565 tumor cell growth Effects 0.000 description 6
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 5
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 5
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 5
- 102000004266 Collagen Type IV Human genes 0.000 description 5
- 108010042086 Collagen Type IV Proteins 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 5
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 238000007747 plating Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 101710110949 Protein S100-A12 Proteins 0.000 description 4
- 102100029812 Protein S100-A12 Human genes 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000008619 cell matrix interaction Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- 238000009650 gentamicin protection assay Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000010232 migration assay Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- -1 poly-D Chemical compound 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100032912 CD44 antigen Human genes 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 102000013566 Plasminogen Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000006427 angiogenic response Effects 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- WNNNWFKQCKFSDK-BYPYZUCNSA-N (2s)-2-aminopent-4-enoic acid Chemical compound OC(=O)[C@@H](N)CC=C WNNNWFKQCKFSDK-BYPYZUCNSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 101000653791 Bos taurus Protein S100-A12 Proteins 0.000 description 2
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 2
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WDEHMRNSGHVNOH-VHSXEESVSA-N Gly-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)CN)C(=O)O WDEHMRNSGHVNOH-VHSXEESVSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 2
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 2
- 241000239218 Limulus Species 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 101001025345 Rattus norvegicus High mobility group protein B1 Proteins 0.000 description 2
- 102000013674 S-100 Human genes 0.000 description 2
- 108700021018 S100 Proteins 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- WNDUPCKKKGSKIQ-CIUDSAMLSA-N Ser-Pro-Gln Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O WNDUPCKKKGSKIQ-CIUDSAMLSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000003366 colagenolytic effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 108010089804 glycyl-threonine Proteins 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000008611 intercellular interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 108010057821 leucylproline Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000001991 pathophysiological effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000004647 pro-inflammatory pathway Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 108010029020 prolylglycine Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 230000005951 type IV hypersensitivity Effects 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 235000019871 vegetable fat Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZDRLKQLULCHOAJ-SECBINFHSA-N (2S)-2-amino-2,3,3-trifluoro-3-(4-hydroxyphenyl)propanoic acid Chemical compound FC([C@](N)(C(=O)O)F)(C1=CC=C(C=C1)O)F ZDRLKQLULCHOAJ-SECBINFHSA-N 0.000 description 1
- RRUYWEMUWIRRNB-LURJTMIESA-N (2s)-6-amino-2-[carboxy(methyl)amino]hexanoic acid Chemical compound OC(=O)N(C)[C@H](C(O)=O)CCCCN RRUYWEMUWIRRNB-LURJTMIESA-N 0.000 description 1
- IXNRIBJPEOUGGB-DIKMWTQISA-N (2s)-6-amino-n-[(2r)-2-aminohexanoyl]-n-[(2s)-2-amino-3-(4-hydroxycyclohexyl)propanoyl]-2-(4-nitroanilino)hexanamide Chemical compound C([C@H](N)C(=O)N(C(=O)[C@H](N)CCCC)C(=O)[C@H](CCCCN)NC=1C=CC(=CC=1)[N+]([O-])=O)C1CCC(O)CC1 IXNRIBJPEOUGGB-DIKMWTQISA-N 0.000 description 1
- BENKAPCDIOILGV-RQJHMYQMSA-N (2s,4r)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1C[C@H](O)C[C@H]1C(O)=O BENKAPCDIOILGV-RQJHMYQMSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- XBQADBXCNQPHHY-NSHDSACASA-N 33305-77-0 Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C([N+]([O-])=O)C=C1 XBQADBXCNQPHHY-NSHDSACASA-N 0.000 description 1
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- NIGWMJHCCYYCSF-QMMMGPOBSA-N 4-chloro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-QMMMGPOBSA-N 0.000 description 1
- JBMAUZQHVVHPEL-UHFFFAOYSA-N 4-hydroxy-3-nitrobenzenesulfonic acid Chemical compound OC1=CC=C(S(O)(=O)=O)C=C1[N+]([O-])=O JBMAUZQHVVHPEL-UHFFFAOYSA-N 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- XDOLZJYETYVRKV-UHFFFAOYSA-N 7-Aminoheptanoic acid Chemical compound NCCCCCCC(O)=O XDOLZJYETYVRKV-UHFFFAOYSA-N 0.000 description 1
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- JBGSZRYCXBPWGX-BQBZGAKWSA-N Ala-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CCCN=C(N)N JBGSZRYCXBPWGX-BQBZGAKWSA-N 0.000 description 1
- CSAHOYQKNHGDHX-ACZMJKKPSA-N Ala-Gln-Asn Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CSAHOYQKNHGDHX-ACZMJKKPSA-N 0.000 description 1
- CZPAHAKGPDUIPJ-CIUDSAMLSA-N Ala-Gln-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O CZPAHAKGPDUIPJ-CIUDSAMLSA-N 0.000 description 1
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 1
- OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 description 1
- YHKANGMVQWRMAP-DCAQKATOSA-N Ala-Leu-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YHKANGMVQWRMAP-DCAQKATOSA-N 0.000 description 1
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 1
- RAAWHFXHAACDFT-FXQIFTODSA-N Ala-Met-Asn Chemical compound CSCC[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CC(N)=O)C(O)=O RAAWHFXHAACDFT-FXQIFTODSA-N 0.000 description 1
- BTRULDJUUVGRNE-DCAQKATOSA-N Ala-Pro-Lys Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O BTRULDJUUVGRNE-DCAQKATOSA-N 0.000 description 1
- REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000012936 Angiostatins Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- NONSEUUPKITYQT-BQBZGAKWSA-N Arg-Asn-Gly Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)O)N)CN=C(N)N NONSEUUPKITYQT-BQBZGAKWSA-N 0.000 description 1
- QIWYWCYNUMJBTC-CIUDSAMLSA-N Arg-Cys-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O QIWYWCYNUMJBTC-CIUDSAMLSA-N 0.000 description 1
- UPKMBGAAEZGHOC-RWMBFGLXSA-N Arg-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O UPKMBGAAEZGHOC-RWMBFGLXSA-N 0.000 description 1
- UAOSDDXCTBIPCA-QXEWZRGKSA-N Arg-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UAOSDDXCTBIPCA-QXEWZRGKSA-N 0.000 description 1
- AWMAZIIEFPFHCP-RCWTZXSCSA-N Arg-Pro-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O AWMAZIIEFPFHCP-RCWTZXSCSA-N 0.000 description 1
- JWCCFNZJIRZUCL-AVGNSLFASA-N Arg-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N JWCCFNZJIRZUCL-AVGNSLFASA-N 0.000 description 1
- UTSMXMABBPFVJP-SZMVWBNQSA-N Arg-Val-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UTSMXMABBPFVJP-SZMVWBNQSA-N 0.000 description 1
- WHLDJYNHXOMGMU-JYJNAYRXSA-N Arg-Val-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WHLDJYNHXOMGMU-JYJNAYRXSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OLGCWMNDJTWQAG-GUBZILKMSA-N Asn-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(N)=O OLGCWMNDJTWQAG-GUBZILKMSA-N 0.000 description 1
- WMLFFCRUSPNENW-ZLUOBGJFSA-N Asp-Ser-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O WMLFFCRUSPNENW-ZLUOBGJFSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 238000007808 Cell invasion assay Methods 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 238000003591 CyQUANT Cell Proliferation Assay Kit Methods 0.000 description 1
- CIVXDCMSSFGWAL-YUMQZZPRSA-N Cys-Lys-Gly Chemical compound C(CCN)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CS)N CIVXDCMSSFGWAL-YUMQZZPRSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- PRBLYKYHAJEABA-SRVKXCTJSA-N Gln-Arg-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O PRBLYKYHAJEABA-SRVKXCTJSA-N 0.000 description 1
- IKDOHQHEFPPGJG-FXQIFTODSA-N Gln-Asp-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O IKDOHQHEFPPGJG-FXQIFTODSA-N 0.000 description 1
- ZNZPKVQURDQFFS-FXQIFTODSA-N Gln-Glu-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZNZPKVQURDQFFS-FXQIFTODSA-N 0.000 description 1
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 1
- KKCJHBXMYYVWMX-KQXIARHKSA-N Gln-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N KKCJHBXMYYVWMX-KQXIARHKSA-N 0.000 description 1
- DYVMTEWCGAVKSE-HJGDQZAQSA-N Gln-Thr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O DYVMTEWCGAVKSE-HJGDQZAQSA-N 0.000 description 1
- RSUVOPBMWMTVDI-XEGUGMAKSA-N Glu-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)C)C(O)=O)=CNC2=C1 RSUVOPBMWMTVDI-XEGUGMAKSA-N 0.000 description 1
- ITBHUUMCJJQUSC-LAEOZQHASA-N Glu-Ile-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O ITBHUUMCJJQUSC-LAEOZQHASA-N 0.000 description 1
- INGJLBQKTRJLFO-UKJIMTQDSA-N Glu-Ile-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O INGJLBQKTRJLFO-UKJIMTQDSA-N 0.000 description 1
- DWBBKNPKDHXIAC-SRVKXCTJSA-N Glu-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCC(O)=O DWBBKNPKDHXIAC-SRVKXCTJSA-N 0.000 description 1
- SYWCGQOIIARSIX-SRVKXCTJSA-N Glu-Pro-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O SYWCGQOIIARSIX-SRVKXCTJSA-N 0.000 description 1
- NNQDRRUXFJYCCJ-NHCYSSNCSA-N Glu-Pro-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O NNQDRRUXFJYCCJ-NHCYSSNCSA-N 0.000 description 1
- GPSHCSTUYOQPAI-JHEQGTHGSA-N Glu-Thr-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O GPSHCSTUYOQPAI-JHEQGTHGSA-N 0.000 description 1
- YOTHMZZSJKKEHZ-SZMVWBNQSA-N Glu-Trp-Lys Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CCC(O)=O)=CNC2=C1 YOTHMZZSJKKEHZ-SZMVWBNQSA-N 0.000 description 1
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 1
- RMWAOBGCZZSJHE-UMNHJUIQSA-N Glu-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N RMWAOBGCZZSJHE-UMNHJUIQSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- JRDYDYXZKFNNRQ-XPUUQOCRSA-N Gly-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN JRDYDYXZKFNNRQ-XPUUQOCRSA-N 0.000 description 1
- DTPOVRRYXPJJAZ-FJXKBIBVSA-N Gly-Arg-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N DTPOVRRYXPJJAZ-FJXKBIBVSA-N 0.000 description 1
- LXXLEUBUOMCAMR-NKWVEPMBSA-N Gly-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)CN)C(=O)O LXXLEUBUOMCAMR-NKWVEPMBSA-N 0.000 description 1
- SOEATRRYCIPEHA-BQBZGAKWSA-N Gly-Glu-Glu Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SOEATRRYCIPEHA-BQBZGAKWSA-N 0.000 description 1
- FCKPEGOCSVZPNC-WHOFXGATSA-N Gly-Ile-Phe Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FCKPEGOCSVZPNC-WHOFXGATSA-N 0.000 description 1
- CCBIBMKQNXHNIN-ZETCQYMHSA-N Gly-Leu-Gly Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CCBIBMKQNXHNIN-ZETCQYMHSA-N 0.000 description 1
- GLACUWHUYFBSPJ-FJXKBIBVSA-N Gly-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN GLACUWHUYFBSPJ-FJXKBIBVSA-N 0.000 description 1
- FFJQHWKSGAWSTJ-BFHQHQDPSA-N Gly-Thr-Ala Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O FFJQHWKSGAWSTJ-BFHQHQDPSA-N 0.000 description 1
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 1
- YGHSQRJSHKYUJY-SCZZXKLOSA-N Gly-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN YGHSQRJSHKYUJY-SCZZXKLOSA-N 0.000 description 1
- SBVMXEZQJVUARN-XPUUQOCRSA-N Gly-Val-Ser Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O SBVMXEZQJVUARN-XPUUQOCRSA-N 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 108010027339 H-norleucyl-hexahydrotyrosyl-lysine-4-nitroanilide Proteins 0.000 description 1
- ZUPVLBAXUUGKKN-VHSXEESVSA-N His-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CC2=CN=CN2)N)C(=O)O ZUPVLBAXUUGKKN-VHSXEESVSA-N 0.000 description 1
- VFBZWZXKCVBTJR-SRVKXCTJSA-N His-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N VFBZWZXKCVBTJR-SRVKXCTJSA-N 0.000 description 1
- VIJMRAIWYWRXSR-CIUDSAMLSA-N His-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 VIJMRAIWYWRXSR-CIUDSAMLSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- OVPYIUNCVSOVNF-KQXIARHKSA-N Ile-Gln-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N OVPYIUNCVSOVNF-KQXIARHKSA-N 0.000 description 1
- OVPYIUNCVSOVNF-ZPFDUUQYSA-N Ile-Gln-Pro Natural products CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O OVPYIUNCVSOVNF-ZPFDUUQYSA-N 0.000 description 1
- XLCZWMJPVGRWHJ-KQXIARHKSA-N Ile-Glu-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N XLCZWMJPVGRWHJ-KQXIARHKSA-N 0.000 description 1
- GTSAALPQZASLPW-KJYZGMDISA-N Ile-His-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N GTSAALPQZASLPW-KJYZGMDISA-N 0.000 description 1
- FZWVCYCYWCLQDH-NHCYSSNCSA-N Ile-Leu-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N FZWVCYCYWCLQDH-NHCYSSNCSA-N 0.000 description 1
- PMMMQRVUMVURGJ-XUXIUFHCSA-N Ile-Leu-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O PMMMQRVUMVURGJ-XUXIUFHCSA-N 0.000 description 1
- AGGIYSLVUKVOPT-HTFCKZLJSA-N Ile-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N AGGIYSLVUKVOPT-HTFCKZLJSA-N 0.000 description 1
- CNMOKANDJMLAIF-CIQUZCHMSA-N Ile-Thr-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O CNMOKANDJMLAIF-CIQUZCHMSA-N 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
- 108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- QWCKQJZIFLGMSD-VKHMYHEASA-N L-alpha-aminobutyric acid Chemical compound CC[C@H](N)C(O)=O QWCKQJZIFLGMSD-VKHMYHEASA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- UCUNFLYVYCGDHP-UHFFFAOYSA-N L-methionine sulfone Natural products CS(=O)(=O)CCC(N)C(O)=O UCUNFLYVYCGDHP-UHFFFAOYSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- DGYHPLMPMRKMPD-BYPYZUCNSA-N L-propargylglycine Chemical compound OC(=O)[C@@H](N)CC#C DGYHPLMPMRKMPD-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000002297 Laminin Receptors Human genes 0.000 description 1
- 108010000851 Laminin Receptors Proteins 0.000 description 1
- FIJMQLGQLBLBOL-HJGDQZAQSA-N Leu-Asn-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FIJMQLGQLBLBOL-HJGDQZAQSA-N 0.000 description 1
- GPICTNQYKHHHTH-GUBZILKMSA-N Leu-Gln-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O GPICTNQYKHHHTH-GUBZILKMSA-N 0.000 description 1
- YWKNKRAKOCLOLH-OEAJRASXSA-N Leu-Phe-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=CC=C1 YWKNKRAKOCLOLH-OEAJRASXSA-N 0.000 description 1
- WMIOEVKKYIMVKI-DCAQKATOSA-N Leu-Pro-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WMIOEVKKYIMVKI-DCAQKATOSA-N 0.000 description 1
- KWLWZYMNUZJKMZ-IHRRRGAJSA-N Leu-Pro-Leu Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O KWLWZYMNUZJKMZ-IHRRRGAJSA-N 0.000 description 1
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 1
- HWMQRQIFVGEAPH-XIRDDKMYSA-N Leu-Ser-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 HWMQRQIFVGEAPH-XIRDDKMYSA-N 0.000 description 1
- LINKCQUOMUDLKN-KATARQTJSA-N Leu-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N)O LINKCQUOMUDLKN-KATARQTJSA-N 0.000 description 1
- HOMFINRJHIIZNJ-HOCLYGCPSA-N Leu-Trp-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(O)=O HOMFINRJHIIZNJ-HOCLYGCPSA-N 0.000 description 1
- FDBTVENULFNTAL-XQQFMLRXSA-N Leu-Val-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N FDBTVENULFNTAL-XQQFMLRXSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- WGLAORUKDGRINI-WDCWCFNPSA-N Lys-Glu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WGLAORUKDGRINI-WDCWCFNPSA-N 0.000 description 1
- UQJOKDAYFULYIX-AVGNSLFASA-N Lys-Pro-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 UQJOKDAYFULYIX-AVGNSLFASA-N 0.000 description 1
- GHKXHCMRAUYLBS-CIUDSAMLSA-N Lys-Ser-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O GHKXHCMRAUYLBS-CIUDSAMLSA-N 0.000 description 1
- VKCPHIOZDWUFSW-ONGXEEELSA-N Lys-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN VKCPHIOZDWUFSW-ONGXEEELSA-N 0.000 description 1
- DRRXXZBXDMLGFC-IHRRRGAJSA-N Lys-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN DRRXXZBXDMLGFC-IHRRRGAJSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- YRAWWKUTNBILNT-FXQIFTODSA-N Met-Ala-Ala Chemical group CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YRAWWKUTNBILNT-FXQIFTODSA-N 0.000 description 1
- YYEIFXZOBZVDPH-DCAQKATOSA-N Met-Lys-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O YYEIFXZOBZVDPH-DCAQKATOSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 101710159910 Movement protein Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 108050003738 Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- PEMUHKUIQHFMTH-UHFFFAOYSA-N P-Bromo-DL-phenylalanine Chemical compound OC(=O)C(N)CC1=CC=C(Br)C=C1 PEMUHKUIQHFMTH-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- IIEOLPMQYRBZCN-SRVKXCTJSA-N Phe-Ser-Cys Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O IIEOLPMQYRBZCN-SRVKXCTJSA-N 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920000037 Polyproline Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- QBFONMUYNSNKIX-AVGNSLFASA-N Pro-Arg-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O QBFONMUYNSNKIX-AVGNSLFASA-N 0.000 description 1
- XROLYVMNVIKVEM-BQBZGAKWSA-N Pro-Asn-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O XROLYVMNVIKVEM-BQBZGAKWSA-N 0.000 description 1
- PZSCUPVOJGKHEP-CIUDSAMLSA-N Pro-Gln-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PZSCUPVOJGKHEP-CIUDSAMLSA-N 0.000 description 1
- NMELOOXSGDRBRU-YUMQZZPRSA-N Pro-Glu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCCN1 NMELOOXSGDRBRU-YUMQZZPRSA-N 0.000 description 1
- HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 description 1
- FKLSMYYLJHYPHH-UWVGGRQHSA-N Pro-Gly-Leu Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O FKLSMYYLJHYPHH-UWVGGRQHSA-N 0.000 description 1
- HFNPOYOKIPGAEI-SRVKXCTJSA-N Pro-Leu-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 HFNPOYOKIPGAEI-SRVKXCTJSA-N 0.000 description 1
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 1
- BNUKRHFCHHLIGR-JYJNAYRXSA-N Pro-Trp-Asp Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(=O)O)C(=O)O BNUKRHFCHHLIGR-JYJNAYRXSA-N 0.000 description 1
- KHRLUIPIMIQFGT-AVGNSLFASA-N Pro-Val-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHRLUIPIMIQFGT-AVGNSLFASA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- YRBGKVIWMNEVCZ-WDSKDSINSA-N Ser-Glu-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O YRBGKVIWMNEVCZ-WDSKDSINSA-N 0.000 description 1
- LALNXSXEYFUUDD-GUBZILKMSA-N Ser-Glu-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LALNXSXEYFUUDD-GUBZILKMSA-N 0.000 description 1
- GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 description 1
- VZQRNAYURWAEFE-KKUMJFAQSA-N Ser-Leu-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 VZQRNAYURWAEFE-KKUMJFAQSA-N 0.000 description 1
- MQUZANJDFOQOBX-SRVKXCTJSA-N Ser-Phe-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O MQUZANJDFOQOBX-SRVKXCTJSA-N 0.000 description 1
- KIEIJCFVGZCUAS-MELADBBJSA-N Ser-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)N)C(=O)O KIEIJCFVGZCUAS-MELADBBJSA-N 0.000 description 1
- PMTWIUBUQRGCSB-FXQIFTODSA-N Ser-Val-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O PMTWIUBUQRGCSB-FXQIFTODSA-N 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000012288 TUNEL assay Methods 0.000 description 1
- TYVAWPFQYFPSBR-BFHQHQDPSA-N Thr-Ala-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(O)=O TYVAWPFQYFPSBR-BFHQHQDPSA-N 0.000 description 1
- LVHHEVGYAZGXDE-KDXUFGMBSA-N Thr-Ala-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)O)N)O LVHHEVGYAZGXDE-KDXUFGMBSA-N 0.000 description 1
- DSLHSTIUAPKERR-XGEHTFHBSA-N Thr-Cys-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O DSLHSTIUAPKERR-XGEHTFHBSA-N 0.000 description 1
- KZTLZZQTJMCGIP-ZJDVBMNYSA-N Thr-Val-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KZTLZZQTJMCGIP-ZJDVBMNYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- NMOIRIIIUVELLY-WDSOQIARSA-N Trp-Val-Leu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)C(C)C)=CNC2=C1 NMOIRIIIUVELLY-WDSOQIARSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- QYSBJAUCUKHSLU-JYJNAYRXSA-N Tyr-Arg-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O QYSBJAUCUKHSLU-JYJNAYRXSA-N 0.000 description 1
- KWKJGBHDYJOVCR-SRVKXCTJSA-N Tyr-Ser-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O KWKJGBHDYJOVCR-SRVKXCTJSA-N 0.000 description 1
- ZLFHAAGHGQBQQN-GUBZILKMSA-N Val-Ala-Pro Natural products CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O ZLFHAAGHGQBQQN-GUBZILKMSA-N 0.000 description 1
- SLLKXDSRVAOREO-KZVJFYERSA-N Val-Ala-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)N)O SLLKXDSRVAOREO-KZVJFYERSA-N 0.000 description 1
- CELJCNRXKZPTCX-XPUUQOCRSA-N Val-Gly-Ala Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O CELJCNRXKZPTCX-XPUUQOCRSA-N 0.000 description 1
- PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 description 1
- PMDOQZFYGWZSTK-LSJOCFKGSA-N Val-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C PMDOQZFYGWZSTK-LSJOCFKGSA-N 0.000 description 1
- AEMPCGRFEZTWIF-IHRRRGAJSA-N Val-Leu-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O AEMPCGRFEZTWIF-IHRRRGAJSA-N 0.000 description 1
- BTWMICVCQLKKNR-DCAQKATOSA-N Val-Leu-Ser Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C([O-])=O BTWMICVCQLKKNR-DCAQKATOSA-N 0.000 description 1
- IJGPOONOTBNTFS-GVXVVHGQSA-N Val-Lys-Glu Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O IJGPOONOTBNTFS-GVXVVHGQSA-N 0.000 description 1
- LGXUZJIQCGXKGZ-QXEWZRGKSA-N Val-Pro-Asn Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)N)C(=O)O)N LGXUZJIQCGXKGZ-QXEWZRGKSA-N 0.000 description 1
- DVLWZWNAQUBZBC-ZNSHCXBVSA-N Val-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N)O DVLWZWNAQUBZBC-ZNSHCXBVSA-N 0.000 description 1
- NLNCNKIVJPEFBC-DLOVCJGASA-N Val-Val-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O NLNCNKIVJPEFBC-DLOVCJGASA-N 0.000 description 1
- AEFJNECXZCODJM-UWVGGRQHSA-N Val-Val-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C(=O)NCC([O-])=O AEFJNECXZCODJM-UWVGGRQHSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 108010027668 glycyl-alanyl-valine Proteins 0.000 description 1
- 108010051307 glycyl-glycyl-proline Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005179 haloacetyl group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 102000056530 human sRAGE Human genes 0.000 description 1
- 108700022230 human sRAGE Proteins 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 230000007728 intracellular signaling mechanism Effects 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 210000001232 limbus corneae Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- HEGSGKPQLMEBJL-UHFFFAOYSA-N n-octyl beta-D-glucopyranoside Natural products CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000033885 plasminogen activation Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- PYHOFAHZHOBVGV-UHFFFAOYSA-N triazane Chemical compound NNN PYHOFAHZHOBVGV-UHFFFAOYSA-N 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 108010029384 tryptophyl-histidine Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- IBIDRSSEHFLGSD-UHFFFAOYSA-N valinyl-arginine Natural products CC(C)C(N)C(=O)NC(C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- RAGE Receptor to AGE
- the present invention provides for a method for inhibiting tumor invasion or metastasis in a subject which comprises administering to the subject a therapeutically effective amount of a form of soluble Receptor for Advanced Glycation Endproducts (RAGE).
- the present invention also provides a method for evaluating the ability of an agent to inhibit tumor invasion in a local cellular environment which comprises: (a) admixing with cell culture media an effective amount of the agent; (b) contacting a tumor cell in cell culture with the media from step (a); (c) determining the amount of spreading of the tumor cell culture, and (d) comparing the amount of spreading of the tumor cell culture determined in step (c) with the amount determined in the absence of the agent, thus evaluating the ability of the agent to inhibit tumor invasion in the local cellular environment.
- the present invention also provides a pharmaceutical composition which comprises a therapeutically effective amount of the agent evaluated in the aforementioned method and a pharmaceutically acceptable carrier.
- FIG. 1 Transfection of C6 glioma cells with constructs expressing sRAGE results in diminished tumor volume compared with mock-transfected tumor cells.
- 1 ⁇ 10 5 tumor cells/ml (0.1 ml) were injected into the backs of nude mice.
- Cells were previously transfected either with constructs overexpressing sRAGE or mock-transfection (vector alone) as described above.
- tumor volume was measured. The mean ⁇ standard error of the mean is reported. Twenty mice were studied per experimental group. Statistical considerations are indicated. This experiment was repeated three times with analogous results.
- FIG. 2 The growth rate of sRAGE-transfected tumor cells is not different than that of mock-transfected tumor cells, in vivo.
- the rate of tumor cell growth was calculated and the slope of the line determined ( ⁇ standard error) using Microsoft Excel.
- the y axis represents the natural logarithm of the tumor volume and the x axis represents time (days).
- FIG. 3 The rate of growth of sRAGE-transfected tumor cells is similar to that of mock-transfected tumor cells in in vitro studies.
- C6 glioma cells transfected with either sRAGE or mock were placed into 96 well tissue culture wells.
- cells were fixed and stained and relative cell number assessed using the CYQUANT® assay from AMERSHAM®.
- FIG. 4 Systemic administration of sRAGE results in diminished tumor volume in C6 glioma cells injected into nude mice.
- C6 glioma cells (1 ⁇ 10 5 /ml; 0.1 ml) were injected into the backs of nude mice.
- MSA mouse serum albumin
- FIG. 5 The rate of growth of C6 glioma cells is similar in sRAGE and MSA-treated mice in vivo. The rate of tumor cell growth was calculated and the slope of the line determined ( ⁇ standard error) using Microsoft Excel. The y axis represents the natural logarithm of the tumor volume and the X axis represents time (days). The slope of the growth curve for C6 glioma tumor cells grown in the presence of mouse serum albumin was 0.264 ⁇ 0.03. The slopes of the growth curve for C6 glioma cells grown in the presence of sRAGE (20 vs. 2 ⁇ g/ml) were not different (0.311 ⁇ 0.04 and 0.313 ⁇ 0.04, respectively).
- FIG. 6 The rate of growth of tumor cells is similar in the presence of either sRAGE or mouse serum albumin in in vitro studies.
- C6 glioma cells were placed into 96 well tissue culture wells and grown in the presence of either sRAGE (20 or 2 ⁇ g/ml) or mouse serum albumin (40 ⁇ g/ml).
- sRAGE 20 or 2 ⁇ g/ml
- mouse serum albumin 40 ⁇ g/ml
- Relative cell number (day three) of cells treated with MSA was 1.0 ⁇ 0.045.
- relative cell number in the presence of sRAGE (20 or 2 ⁇ g/ml) was 1.03 ⁇ 0.06 and 1.02 ⁇ 0.06, respectively.
- Statistical considerations are shown.
- FIG. 7 RAGE and amphoterin are expressed in tumor cells (A); effect of stably-transfected RAGE/RAGE mutant rat C6 glioma cells (B-F); soluble RAGE (G); or anti-RAGE/amphoterin F(ab′) 2 (H) in a model of local tumor growth and invasion. (A1-2).
- RAGE (1) and amphoterin (2) are expressed in tumor cells. Extracts of murine Lewis lung carcinoma cells (lane 2) and rat C6 glioma cells (lane 3) were prepared and subjected to SDS-PAGE and immunoblotting with anti-RAGE IgG (A1) or anti-amphoterin IgG (A2) as described.
- A1 murine soluble recombinant RAGE (0.5 ⁇ g) was employed as positive control (lane 1); in A2, recombinant rat amphoterin (0.5 ⁇ g) was employed (lane 1). Molecular weight markers run simultaneously are indicated in the left margin (kDa). Controls employing preimmune rabbit IgG were negative (not shown).
- B-F Effect of stably-transfected RAGE/RAGE mutant C6 glioma cells implanted into immunocompromised (nude) mice.
- B The indicated clones of RAGE/RAGE mutant C6 glioma cells were injected in the dorsal midline of nude mice. Tumors were followed serially and mice sacrificed on day 21.
- FIG. 8 Blockade of RAGE suppresses distant metastasis.
- A Effect of administration of sRAGE on numbers of lung surface metastases.
- B-E Representative photographs of lungs removed from C57BL/6J mice bearing metastatic Lewis lung carcinoma.
- FIG. 9 Amphoterin/RAGE mediate tumor cell migration and invasion: in vitro analyses.
- A Effect of sRAGE on tumor cell proliferation in vitro. Wild-type rat C6 glioma cells were cultured in the presence of the indicated concentrations of MSA or murine sRAGE. Three days after plating, cell number was assessed using the CyQUANT cell proliferation assay as described. Mean number of cells SE in 16 wells is reported. Statistical considerations are indicated.
- (B) Effect of RAGE/RAGE mutation in clones of stably-transfected rat C6 glioma cells on tumor cell invasion.
- Invasion assays were performed as described employing three different clones of stably-transfected RAGE/RAGE mutant C6 glioma cells.
- the number of cells invading matrigel ⁇ SE in 10 high-powered fields (hpf) is reported.
- Invasion assays employing rat C6 glioma cells were performed in the presence of the indicated concentrations of MSA or sRAGE (C) or anti-RAGE/anti-amphoterin IgG (D). The number of cells invading matrigel ⁇ SE in 10 hpf is reported. Statistical considerations are indicated.
- E Effect of RAGE/RAGE mutation in clones of stably-transfected rat C6 glioma cells on tumor cell migration. Migration assays were performed as described employing three different clones of stably-transfected RAGE/RAGE mutant C6 glioma cells. The number of migrating cells ⁇ standard error in 10 hpf is reported.
- FIG. 10 Lack of effect of RAGE blockade on tumor attachment (A), angiogenesis (B), collagenase (C) or plasmin (D) activity.
- A Attachment assay. Rat C6 glioma cells were employed in an in vitro assay of tumor attachment as described in the presence of sRAGE or MSA. At the indicated times, wells were depleted of medium by aspiration and washed twice. At each point, cell number per well was quantified using the CyQUANT assay kit. The mean % of cells attached compared with total number added ⁇ SE of 16 wells is shown. No statistically-significant difference was observed between cells in the presence of MSA vs sRAGE (p>0.1).
- B Angiogenesis.
- the present invention provides for a method for inhibiting tumor invasion or metastasis in a subject which comprises administering to the subject a therapeutically effective amount of a form of soluble Receptor for Advanced Glycation Endproducts (RAGE).
- RAGE Receptor for Advanced Glycation Endproducts
- a “form of soluble RAGE” encompasses peptides which are derived from naturally occurring RAGE protein.
- Representative peptides of the present invention include but are not limited to peptides having an amino acid sequence which corresponds to amino acid numbers (2-30), (5-35), (10-40), (15-45), (20-50), (25-55), (30-60), (30-65), (10-60), (8-100), 14-75), (24-80), (33-75), (45-110) of human sRAGE protein.
- the form of soluble RAGE may consist essentially of any such portion of the human RAGE peptide.
- the form of soluble RAGE may consist essentially of a peptide which comprises any such portion of the human RAGE amino acid having the sequence from amino acid at position 1 (alanine) to amino acid number 332 (alanine) (without considering the 22 amino acid leader sequence).
- the amino acids may be L- or D-amino acids.
- An amino acid may be replaced by a synthetic amino acid which is altered so as to increase the half-life of the peptide or to increase the potency of the peptide, or to increase the bioavailability of the peptide.
- the form of soluble RAGE comprises a peptide having the sequence from alanine at position 1 to alanine at position 332 of human RAGE.
- the form of soluble RAGE comprises a peptide of 10-40 amino acids having a sequence taken from within the sequence from alanine at position 1 to alanine at position 332 of human RAGE.
- the form of soluble RAGE comprises a peptide having the following sequence of mature human RAGE.
- the form of soluble RAGE comprises a V domain of naturally occurring soluble RAGE. In another embodiment the form of soluble RAGE comprises a C domain of naturally occurring soluble RAGE.
- the 22 amino acid leader sequence of immature human RAGE is Met Ala Ala Gly Thr Ala Val Gly Ala Trp Val Leu Val Leu Ser Leu Trp Gly Ala Val Val Gly (Seq. I.D. No. 2).
- the form of soluble RAGE is a peptide expressed by a replicable vector containing nucleic acid encoding the form of soluble RAGE. In one embodiment the form of soluble RAGE is a peptide which corresponds to all or part of soluble RAGE expressed by a replicable vector containing nucleic acid encoding the form of soluble RAGE.
- the replicable vector is capable of expressing the peptide within a tumor cell in a subject.
- the tumor cell is a eukaryotic cell.
- the replicable vector is a plasmid, an attenuated virus, a phage, a phagemid or a linear nucleic acid.
- the method further comprises administering a pharmaceutically acceptable carrier to the subject during the administration of the form of soluble RAGE.
- the administration is via intralesional, intraperitoneal, intramuscular or intravenous injection; infusion; intrathecal administration; subcutaneous administration; liposome-mediated delivery; or topical, nasal, oral, ocular or otic delivery.
- intrathecal administration includes administration in the cerebrospinal fluid by lumbar puncture.
- the subject is a mammal. In another embodiment, the mammal is a human.
- the form of soluble RAGE is administered daily, weekly or monthly.
- the form of soluble RAGE may be delivered hourly, daily, weekly, monthly, yearly (e.g. in a time release form) or as a one time delivery.
- the delivery may be continuous delivery for a period of time, e.g. intravenous delivery.
- the agent or pharmaceutical composition of the present invention may be delivered intercranially or into the spinal fluid.
- the therapeutically effective amount comprises a dose from about 0.000001 mg/kg body weight to about 100 mg/kg body weight.
- the therapeutically effective amount comprises a dose of from about 100 ng/day/kg body weight to about 200 mg/day/kg body weight.
- the present invention also provides a method for evaluating the ability of an agent to inhibit tumor invasion in a local cellular environment which comprises: (a) admixing with cell culture media an effective amount of the agent; (b) contacting a tumor cell in cell culture with the media from step (a); (c) determining the amount of spreading of the tumor cell culture, and (d) comparing the amount of spreading of the tumor cell culture determined in step (c) with the amount determined in the absence of the agent, thus evaluating the ability of the agent to inhibit tumor invasion in the local cellular environment.
- the tumor cell is a eukaryotic cell. In another embodiment the tumor cell is a cell of a subject. In a further embodiment, the subject is a human, a mouse, a rat, a dog or a non-human primate.
- the agent comprises a peptide, a peptidomimetic, a nucleic acid, a synthetic organic molecule, an inorganic molecule, a carbohydrate, a lipid, an antibody or fragment thereof, or a small molecule.
- the antibody may be a monoclonal antibody.
- the antibody may be a polyclonal antibody.
- the fragment of the antibody comprises a Fab fragment.
- the fragment of the antibody comprises a complementarity determining region or a variable region.
- the agent may be conjugated to a carrier.
- the peptide or agent may be linked to an antibody, such as a Fab or a Fc fragment for specifically targeted delivery.
- the peptide is a synthetic peptide or a peptide analog.
- the peptide may be a non-natural peptide which has chirality not found in nature, i.e. D-amino acids or L-amino acids.
- the peptide comprises at least a portion of the sequence -Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-val-His-His-Gln-Lys-Leu-Val-Phe-phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val- (Seq. I.D. No. 3).
- the peptide comprises at least a portion of the sequence -Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met- (Seq. I.D. No. 4).
- the peptide has the amino acid sequence A-Q-N-I-T-A-R-I-G-E-P-L-V-L-K-C-K-G-A-P-K-K-P-P-Q-R-L-E-W-K (Seq. I.D. No. 5).
- the peptide has the amino acid sequence A-Q-N-I-T-A-R-I-G-E (Seq. I.D. No. 6).
- the present invention also embraces other peptides such as peptide analogs of sRAGE.
- Such analogs include fragments of sRAGE.
- Alton et al. WO 83/04053
- modifications of cDNA and genomic genes can be readily accomplished by well-known site-directed mutagenesis techniques and employed to generate analogs and derivatives of sRAGE polypeptide.
- products of the invention include those which are foreshortened by e.g., deletions; or those which are more stable to hydrolysis (and, therefore, may have more pronounced or longerlasting effects than naturally-occurring); or which have been altered to delete or to add one or more potential sites for O-glycosylation and/or N-glycosylation or which have one or more cysteine residues deleted or replaced by e.g., alanine or serine residues and are potentially more easily isolated in active form from microbial systems; or which have one or more tyrosine residues replaced by phenylalanine and bind more or less readily to target proteins or to receptors on target cells.
- polypeptide fragments duplicating only a part of the continuous amino acid sequence or secondary conformations within sRAGE which fragments may possess one property of sRAGE and not others. It is noteworthy that activity is not necessary for any one or more of the polypeptides of the invention to have therapeutic utility or utility in other contexts, such as in assays of sRAGE antagonism.
- Competitive antagonists may be quite useful in, for example, cases of overproduction of sRAGE.
- the agent of the present invention may be a peptidomimetic which may be at least partially unnatural.
- the agent may be a small molecule mimic of a portion of the amino acid sequence of sRAGE.
- the agent may have increased stability, efficacy, potency and bioavailability by virtue of the mimic. Further, the agent may have decreased toxicity.
- the peptidomimetic agent may have enhanced mucosal intestinal permeability.
- the agent may be synthetically prepared.
- the agent of the present invention may include L-,D-, DL- or unnatural amino acids, alpha, alpha-disubstituted amino acids, N-alkyl amino acids, lactic acid (an isoelectronic analog of alanine).
- the peptide backbone of the agent may have at least one bond replaced with PSI—[CH ⁇ CH] (Kempf et al. 1991).
- the agent may further include trifluorotyrosine, p-Cl-phenylalanine, p-Br-phenylalanine, poly-L-propargylglycine, poly-D,L-allyl glycine, or poly-L-allyl glycine.
- unnatural amino acids which may be suitable amino acid mimics include ⁇ -alanine, L- ⁇ -amino butyric acid, L- ⁇ -amino butyric acid, L- ⁇ -amino isobutyric acid, L- ⁇ -amino caproic acid, 7-amino heptanoic acid, L-aspartic acid, L-glutamic acid, cysteine (acetamindomethyl), N- ⁇ -Boc-N- ⁇ -CBZ-L-lysine, N- ⁇ -Boc-N- ⁇ -Fmoc-L-lysine, L-methionine sulfone, L-norleucine, L-norvaline, N- ⁇ -Boc-N- ⁇ CBZ-L-ornithine, N- ⁇ -Boc-N- ⁇ -CBZ-L-ornithine, Boc-p-nitro-L-phenylalanine, Boc-hydroxyproline, Boc-L-thi
- the agent is a form of soluble human RAGE. In another embodiment the agent is an extracellular portion human RAGE. In another embodiment the agent inhibits an interaction between the tumor cell and an extracellular matrix molecule. In one embodiment the extracellular matrix molecule is a laminin, a fibronectin, amphoterin, a cadherin, an integrin or a hyaluronic acid. In another embodiment the integrin is an ⁇ V ⁇ V integrin, an ⁇ V ⁇ III integrin, or an ⁇ I ⁇ III integrin. In another embodiment, the laminin is ⁇ 1 laminin. In another embodiment the agent inhibits binding of RAGE to amphoterin.
- the present invention also provides a pharmaceutical composition which comprises a therapeutically effective amount of the agent evaluated in the aforementioned method and a pharmaceutically acceptable carrier.
- the carrier is a diluent, an aerosol, a topical carrier, an aqueous solution, a replicable nucleic acid vector, a liposome, a magnetic bead, a nonaqueous solution or a solid carrier.
- the actual effective amount will be based upon the size of the subject.
- the biodegradability of the agent, the bioactivity of the agent and the bioavailability of the agent are factors which will alter the effective amount.
- the agent may be delivered topically in a cream or salve carrier. It may be reapplied as needed based upon the adsorbancy of the carrier to the skin or mucosa or wound. If the agent does not degrade quickly, is bioavailable and highly active, a smaller amount will be required to be effective.
- the effective amount will be known to one of skill in the art; it will also be dependent upon the form of the agent, the size of the agent and the bioactivity of the agent. One of skill in the art could routinely perform empirical activity tests for a agent to determine the bioactivity in bioassays and thus determine the effective amount.
- the present invention also provides a method for inhibiting tumor invasion or metastasis in a subject which comprises administering to the subject a therapeutically effective amount of the aforementioned pharmaceutical composition.
- One embodiment of the present invention is a composition which comprises a form of soluble RAGE and a pharmaceutically acceptable carrier.
- the invention provides a composition which comprises the aforementioned agent and a pharmaceutically acceptable carrier.
- the term “pharmaceutically acceptable carrier” encompasses any of the standard pharmaceutically accepted carriers, such as phosphate buffered saline solution, acetate buffered saline solution (a likely vehicle for parenteral administration), water, emulsions such as an oil/water emulsion or a triglyceride emulsion, various types of wetting agents, tablets, coated tablets and capsules.
- phosphate buffered saline solution acetate buffered saline solution (a likely vehicle for parenteral administration)
- water emulsions such as an oil/water emulsion or a triglyceride emulsion
- emulsions such as an oil/water emulsion or a triglyceride emulsion
- various types of wetting agents tablets, coated tablets and capsules.
- An example of an acceptable triglyceride emulsion useful in intravenous and intraperitoneal administration of the compounds is the triglyceride
- Such agents and pharmaceutical compositions When administered orally or topically, such agents and pharmaceutical compositions would be delivered using different carriers.
- Such carriers contain excipients such as starch, milk, sugar, certain types of clay, gelatin, stearic acid, talc, vegetable fats or oils, gums, glycols, or other known excipients.
- Such carriers may also include flavor and color additives or other ingredients.
- the specific carrier would need to be selected based upon the desired method of deliver, e.g., PBS could be used for intravenous or systemic delivery and vegetable fats, creams, salves, ointments or gels may be used for topical delivery.
- compositions are liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (e.g., Tris-HCl., acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80, pluronic F68, bile acid salts), solubilizing agents (e.g., glycerol, polyethylene glycerol), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (e.g., lactose, mannitol), covalent attachment of polymers such as polyethylene glycol to the agent, complexation with metal ions, or incorporation of the agent into or onto particulate preparations of polymeric agents such as polylactic acid, polglycolic acid
- the agent of the present invention may be delivered locally via a capsule which allows sustained release of the agent or the peptide over a period of time.
- Controlled or sustained release compositions include formulation in lipophilic depots (e.g., fatty acids, waxes, oils).
- particulate compositions coated with polymers e.g., poloxamers or poloxamines
- the agent coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to ligands of tissue-specific receptors e.g., poloxamers or poloxamines
- Other embodiments of the compositions of the invention incorporate particulate forms protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal and oral.
- agents such as a peptide comprising the V-domain of sRAGE
- agents are often cleared rapidly from the circulation and may therefore elicit relatively short-lived pharmacological activity. Consequently, frequent injections of relatively large doses of bioactive agents may by required to sustain therapeutic efficacy.
- Agents modified by the covalent attachment of water-soluble polymers such as polyethylene glycol, copolymers of polyethylene glycol and polypropylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone or polyproline are known to exhibit substantially longer half-lives in blood following intravenous injection than do the corresponding unmodified agents (Abuchowski et al., 1981; Newmark et al., 1982; and Katre et al., 1987).
- Such modifications may also increase the agent's solubility in aqueous solution, eliminate aggregation, enhance the physical and chemical stability of the agent, and greatly reduce the immunogenicity and reactivity of the agent.
- the desired in vivo biological activity may be achieved by the administration of such polymer-agent adducts less frequently or in lower doses than with the unmodified agent.
- PEG polyethylene glycol
- Attachment of polyethylene glycol (PEG) to agents is particularly useful because PEG has very low toxicity in mammals (Carpenter et al., 1971).
- PEG adduct of adenosine deaminase was approved in the United States for use in humans for the treatment of severe combined immunodeficiency syndrome.
- a second advantage afforded by the conjugation of PEG is that of effectively reducing the immunogenicity and antigenicity of heterologous compounds.
- a PEG adduct of a human protein might be useful for the treatment of disease in other mammalian species without the risk of triggering a severe immune response.
- the agent of the present invention may be delivered in a microencapsulation device so as to reduce or prevent an host immune response against the agent or against cells which may produce the compound.
- the agent of the present invention may also be delivered microencapsulated in a membrane, such as a liposome.
- Polymers such as PEG may be conveniently attached to one or more reactive amino acid residues in a protein such as the alpha-amino group of the amino terminal amino acid, the epsilon amino groups of lysine side chains, the sulfhydryl groups of cysteine side chains, the carboxyl groups of aspartyl and glutamyl side chains, the alpha-carboxyl group of the carboxy-terminal amino acid, tyrosine side chains, or to activated derivatives of glycosyl chains attached to certain asparagine, serine or threonine residues.
- a protein such as the alpha-amino group of the amino terminal amino acid, the epsilon amino groups of lysine side chains, the sulfhydryl groups of cysteine side chains, the carboxyl groups of aspartyl and glutamyl side chains, the alpha-carboxyl group of the carboxy-terminal amino acid, tyrosine side chains, or to activated derivatives of
- PEG reagents for reaction with protein amino groups include active esters of carboxylic acid or carbonate derivatives, particularly those in which the leaving groups are N-hydroxysuccinimide, p-nitrophenol, imidazole or 1-hydroxy-2-nitrobenzene-4-sulfonate.
- PEG derivatives containing maleimido or haloacetyl groups are useful reagents for the modification of protein free sulfhydryl groups.
- PEG reagents containing amino hydrazine or hydrazide groups are useful for reaction with aldehydes generated by periodate oxidation of carbohydrate groups in proteins.
- RAGE Receptor to AGE
- Amphoterin a matrix-associated polypeptide, is expressed in developing neurons and certain tumor cells, such as rat C6 glioma cells (6-12).
- amphoterin may effect matrix degradation by activation of plasminogen: events critical in the ability of tumors to locally invade their immediate environment. Indeed, the ability of tumors to modulate local tissue and vasculature is essential for distal invasion and the development of metastases.
- Soluble RAGE may thus represent a model structure for the development of agents to limit tumor growth and invasion into the local environment, and, potentially, the development of distant metastases.
- C6 glioma cells (rat) we obtained from the American Type Tissue Corporation (ATCC, Rockville, Md.) and characterized as previously described (Singh et al, 1997). Cells were grown as recommended by the ATCC. Transfection of constructs expressing either human soluble RAGE (Neeper et al., 1992) were prepared and transfected into C6 glioma cells using LipoFECTAMINE® (Life Technologies, Grand Island, N.Y.). Stable lines were selected using G418 (Life Technologies). Constructs containing vector alone (mock) were transfected into C6 cells as controls.
- mice were obtained from Taconic Laboratories. At the age of 8-10 weeks, C6 glioma cells (usually about 10 5 cells/ml) were injected into the lower backs of the mice. Tumor volume was measured sequentially and recorded. At sacrifice, mice were deeply anesthetized and then tumors removed and weighed.
- Murine Soluble Rage was prepared using a baculovirus-Sf9 cell expression system.
- Murine sRAGE was purified from cellular supernatant using FPLC Mono S® (Amersham-Pharmacia®) and endotoxin removed using De-Toxigel® columns (Pierce, Rockford, Ill.). The final product was pure based on SDS-PAGE electrophoresis (nonreducing conditions). No detectable endotoxin was found in the final samples ( limulus amebocyte assay. Sigma Chemical Co., St. Louis, Mo.). Control mice were treated with mouse serum albumin (MSA: Sigma Chemical Co.)
- mice Injection of sRAGE into mice. Mice were treated immediately upon injection of the tumor cells into the back of the mouse with the indicated dose of sRAGE or mouse serum albumin (equimolar concentration) through the day of sacrifice. Protein was injected intraperitoneally in a volume of 0.1 ml in phosphate-buffered saline.
- C6 glioma cells were grown onto the wells of 96-well plates. On day, cells were fixed and relative cell number determined using the CYQUANT® assay system from Amersham.
- C6 glioma cells expressed mRNA for RAGE; the presence of RAGE antigen was confirmed by immunohistochemistry.
- C6 glioma cells were transfected with constructs to express either sRAGE or vector alone.
- C6 glioma cells were injected into nude mice; tumors were generated, and then mice were treated parenterally with either sRAGE or mouse serum albumin.
- sRAGE-transfected or mock-transfected C6 glioma cells were injected into nude mice and tumor volume sequentially measured.
- tumor volume was measure on days 14, 17 and 21, substantially smaller tumors were observed in sRAGE-transfected cells compared with mock-transfected tumor cells ( FIG. 1 ).
- mean tumor volume in nude mice injected with mock-transfected tumors was 315,276.5 ⁇ 3,790.4 ⁇ m 3 vs 27,875.4 ⁇ 4,199.6 ⁇ m 3 mean tumor volume in sRAGE-transfected tumor (11.3-fold difference; p ⁇ 0.00005).
- mean tumor volume in nude mice injected with mock-transfected tumor was 823,759 ⁇ 142,841.5 ⁇ m 3 vs.
- the growth rate of the transfected tumor cells derived from analysis of the above in vivo data revealed that there was no difference between the rate of growth of sRAGE-transfected C6 glioma cells compare with those mock-transfected ( FIG. 2 ).
- the slope of the growth curve for mock-transfected tumor cells the slope of the growth curve was 0.241 ⁇ 0.025.
- mean tumor volume in MSA-treated mice was 935,000 ⁇ 117,499 ⁇ m 3 .
- angiogenesis the ability of the tumors to develop tumor-specific vasculature
- matrix degradation in which the ability of matrix metalloproteinases (MMPs) to degrade the surrounding matrix is critical for the local spread and invasiveness of tumors
- TIMPs tissue inhibitors of metalloproteinases
- integrin-cell/integrin/matrix interactions reactions in which specific ligand-receptor contact initiates signaling cascades that eventuate in tumor spread (14-25).
- a current focus of this work is to study the effects of sRAGE in a model of tumor metastases and distal invasion. At this time, studies are underway utilizing Lewis lung carcinoma cells; a model in which distant invasion of the tumor into the pleura and lung parenchyma ensues after removal of the primary lesion (placed onto the lower back of the mice).
- sRAGE may represent a novel structure in the design of agents to limit tumor spread and invasion.
- sRAGE may also exert beneficial effects in the prevention of tumor distal growth and metastases.
- Amphoterin and Rage a Novel Interaction Modulating Tumor Invasion and Migration
- Receptor for AGE a multiligand member of the immunoglobulin superfamily of cell surface molecules, interacts with distinct ligands implicated in development and pathophysiological processes.
- RAGE Receptor for AGE
- Blockade of RAGE-amphoterin interaction potently suppressed primary tumors grown from implanted rat C6 glioma cells, and lung metastases in mice bearing Lewis lung carcinoma.
- RAGE Receptor for Advanced Glycation Endproducts
- a multiligand member of the immunoglobulin superfamily of cell surface molecules (Schmidt et al., 1992; Neeper et al., 1992) interacts with distinct ligands implicated in development and homeostasis (Hori et al., 1995), as well as in certain pathophysiologic situations, such as diabetes, Alzheimer's disease and inflammation (Park et al., 1998; Wautier et al., 1996; Yan et al., 1996; Yan et al., 1997 and Hofmann et al., 1998).
- RAGE was first identified as a signal transduction receptor for products of nonenzymatic glycation and oxidation of proteins/lipids, the Advanced Glycation Endproducts, or AGEs, whose accumulation in disorders such as diabetes has been linked to the pathogenesis of vascular and inflammatory cell complications (Brownlee et al., 1988; and Sell and Monnier, 1989).
- RAGE as a neuronal/microglial interaction site for amyloid-beta peptide (A ⁇ ) (Yan et al., 1996; Yan et al., 1997), the proteolytic cleavage product of beta-amyloid precursor protein, whose accumulation in Alzheimer disease brain has been linked to inflammation and neuronal toxicity (Selkoe, 1994; Sisodia and Price, 1995).
- EN-RAGE Extracellular Novel RAGE binding protein
- S100/calgranulin family of proinflammatory cytokines Schond and Heinzmann, 1996; and Zimmer, et al., 1995
- DTH delayed-type hypersensitivity
- colitis Hofmann, et al., 1998
- RAGE as an integral participant in the cellular response to pathophysiologic stimuli.
- immunoglobulin superfamily receptor was unlikely to have evolved solely to mediate interaction with pathologic ligands, suggesting a possible unexplored aspect of the biology of RAGE in development and/or homeostasis.
- RAGE as a cellular receptor for amphoterin (Hori, et al., 1995), a polypeptide linked to neurite outgrowth in cultured cortical neurons (Rauvala and Pihlaskari, 1987; Rauvala et al., 1988; Parkkinen and Rauvala, 1991; and Parkkinen et al., 1993).
- the extracellular region of RAGE is composed of one V-type followed by two “C”-type immunoglobulin-like domains, and comprises the soluble, ligand-bearing portion of the receptor (Neeper et al., 1992). Following the extracellular and hydrophobic transmembrane spanning domains is a short, highly-charged cytosolic tail. Recent studies have shown the cytosolic tail of the receptor to be essential for RAGE-dependent intracellular signalling and subsequent cellular activation (Fu et al., 1998; Hofmann et al., 1998).
- two strategies for blocking PAGE-mediated cellular stimulation are: 1) expression of a RAGE mutant devoid of the cytosolic tail, producing a truncated form of the receptor present on the cell surface and competent for ligand binding, but one which exerts a dominant-negative effect with respect to RAGE signalling; and, 2) expression of a truncated soluble (s) form of RAGE comprising only the extracellular domain termed sRAGE, which binds up RAGE ligands preventing their access to the cell surface receptor.
- Stably-transfected clones of C6 glioma cells were produced overexpressing either full-length RAGE (F), the tail-deletion RAGE mutant (T) or sRAGE (S) (Table 1).
- tumor volume was decreased ⁇ 3-fold (196 ⁇ 31 mm 3 ) in tumors derived from C6 glioma cell clones transfected with the tail-deletion mutant (FIG. 7 B,C) (p ⁇ 0.01). Further support for a role of RAGE-mediated cellular activation in modulating tumor cell phenotype was emphasized by the ⁇ 6.5-fold (93 ⁇ 23 mm 3 ) suppression of tumor volume observed in neoplasms derived from sRAGE-transfected C6 glioma cells ( FIG. 7B , F) (p ⁇ 0.001).
- soluble receptor was administered once daily to nude mice immediately upon injection of rat C6 glioma cells (Wautier et al., 1996; Park et al., 1998).
- Systemically administered sRAGE caused dose-dependent suppression of tumor volume ( FIG. 7G ), though the effect was less dramatic than with tumor mutants producing sRAGE (S1,2,3; Table 1), probably due to higher local concentrations of soluble receptor in sRAGE-transfected tumors.
- SRAGE was administered just prior to and after resection of primary tumor.
- murine serum albumin (MSA) administration of sRAGE resulted in dose-dependent suppression of lung surface metastases ( FIG. 8A ).
- Blockade of RAGE and/or amphoterin suppresses invasion and migration of C6 glioma cells in vitro analyses. It is essential to note that tumors produced by each of the C6 glioma cell transfectants (F, S, and T) demonstrated the same growth rate as tumors from mock-transfected control C6 cells (M), based on the slope of plots of the natural log of tumor volume versus time post-tumor cell inoculation (Table 2). Furthermore, tumor cell proliferation in vitro, comparing wild-type C6 glioma cells with each of the stable transfectants (M, F, T and S), was unchanged (not shown), and incubation of C6 glioma cells with sRAGE was without effect ( FIG. 9A ).
- angiogenesis assessed in the mouse cornea assay was not adversely affected by administration of sRAGE.
- proliferation of cultured HUVEC was not significantly altered in the presence of sRAGE when compared with cells treated with MSA (data not shown).
- Primary differences in tissue-degradative capacity were also not evident in tumor cells treated with either MSA or sRAGE, as measured by activity of type IV collagenase ( FIG. 10C ) or plasmin ( FIG. 10D ).
- Molecular mechanisms underlying tumorigenesis comprise a complex mesh of processes promoting unchecked cellular proliferation, invasion and induction of neovessel formation, as well as means of evading the immune response and buttressing metabolic adaptation to nutritional stress.
- Upregulation of both amphoterin and RAGE in tumor cells provides an autocrine means for modulating cellular properties in a sustained manner within the neoplasm.
- Previous studies showed that amphoterin engagement of RAGE on neuron-like cells induced neurite outgrowth and enhanced expression of the receptor via Sp1 sites within the promoter of the RAGE gene (Li et al., 1998; Li and Schmidt, 1997).
- amphoterin and RAGE have been colocalized to the leading edges of neurites (Parkkinen et al., 1993; Hori et al., 1995). These observations suggested the potential of RAGE-mediated modification of cellular properties to impart invasiveness, and implied that the impact of amphoterin-RAGE interaction might confer an ascending spiral of abnormal cellular behavior; increased expression of amphoterin causing, in turn, enhanced expression of the receptor, thereby further accentuating amphoterin-RAGE-induced changes in cellular properties. Signals regulating RAGE and amphoterin expression might thus contribute importantly to tumor cell phenotype.
- the intracellular domains of integrins are connected to cytoskeletal proteins and intracellular signal transduction pathways; these domains are postulated to mediate “inside-out” signalling, thereby modulating intercellular communication, cellular differentiation and phenotype (Ginsberg et al., 1992; Heino, 1996). Studies are in progress to delineate components of the molecular complex through which the cytosolic domain of RAGE engages signal transduction machinery and triggers effector mechanisms promoting cellular migratory and invasive properties.
- Amphoterin-RAGE modulation of tumor cell properties is distinct from that of other pathways directly regulating cellular proliferation, angiogenesis, tumor cell-matrix interaction or degradation of critical barrier substrates, such as fibronectin and collagen type IV.
- amphoterin binding to RAGE neither increased the rate of tumor cell growth nor changed tumor cell apoptotic index or p53 expression (Hartwell and Kastan, 1994) (not shown). Blockade of RAGE was without effect on neovessel ingrowth, attachment of tumor cells to matrix elements or tumor cell digestion of basement membrane molecules.
- the amphoterin-RAGE axis appeared to exert effects distinct from other well-studied regulators of tumor cell division, neovessel formation, and cell-matrix interactions.
- Rat glial cells C6
- murine Lewis lung carcinoma cells LLC
- NIH/3T3 cells were purchased from the American Type Culture Corporation (ATCC; Rockville, Md.) and cultured according to standard ATCC protocols.
- Human umbilical vein endothelial cells (HUVEC) were isolated and characterized as previously described (Jaffe et al., 1973) and maintained in Endothelial Cell Growth Medium (EGM; Clonetics, Walkersville Md.) according to the manufacturer's instructions.
- RAGE constructs Human RAGE cDNA (Neeper et al., 1992) was inserted into the mammalian expression vector pcDNA3 (Invitrogen, Carlsbad Calif.) behind the human cytomegalovirus major intermediate early promoter/enhancer region by employing enzyme restriction sites Kpn1 and XhoI.
- Human cytosolic tail deletion RAGE cDNA was composed of a construct in which the entire cytosolic domain coding sequence was deleted (Neeper et al., 1992) and inserted into pcDNA3 vector by employing EcoRV and Xba1 enzyme restriction sites.
- Human soluble RAGE cDNA was composed of a construct in which both the transmembrane spanning domain and cytosolic domain coding sequences were deleted (Neeper et al., 1992) and inserted into pcDNA3 vector by employing EcoRV and Xba1 enzyme restriction sites. All constructs were first transiently-transfected into NIH 3T3 cells and evidence for expression was determined by immunoblotting employing monospecific, polyclonal anti-human RAGE IgG as previously characterized (Schmidt et al., 1992; Hori et al., 1995). This antibody was selectively prepared against soluble human RAGE, therefore, it recognizes the products of all three cDNA constructs.
- C6 rat glioma cells were transfected by employing Lipofectamine (Life Technologies, Grand Island, N.Y.) according to the manufacturer's instructions. Cells were selected in the presence of geneticin (G418), 1.5 mg/ml (Life Technologies), and individual clones were isolated by means of limiting dilution (Pelicci et al., 1992). Selected clones were tested for RAGE expression by immunoblotting (Schmidt et al., 1992).
- transfected lines were produced as follows: (1) mock transfectants (M), transfected with vector alone but grown and maintained exactly as the RAGE transfectants; (2) full-length RAGE transfectants (F), transfected with construct encoding full-length human RAGE; (3) tail-deletion RAGE transfectants (T), transfected with construct encoding RAGE lacking the cytosolic domain; and (4) soluble RAGE transfectants (S); transfected with construct in which both the transmembrane spanning domain and cytosolic domains were deleted. In each case, three independent clones were established for each transfected cell line.
- Murine soluble RAGE Production of murine soluble RAGE.
- the construct encoding murine soluble RAGE was placed into the baculovirus expression system and soluble murine RAGE expressed in Spodoptera frugiperda 9 (Sf9) cells (Invitrogen).
- Murine sRAGE was purified from cellular supernatant as previously described (Park et al., 1998) and devoid of endotoxin prior to intraperitoneal administration to mice by chromatography onto Detox-igel columns (Pierce, Arlington Heights, Ill.). Absence of endotoxin was documented using a kit from Sigma (St. Louis, Mo.) ( limulus amebocyte assay).
- Murine serum albumin was purchased from Sigma.
- Immunoblotting of cultured tumor cells was performed by subjecting cells to sonication with a Branson Ultrasonics 250 Sonicator (Branson Ultrasonics, Danbury Conn.) in buffer containing tris, 0.02M, pH 7.4; NaCl, 0.1 M; PMSF, 0.002M; leupeptin, 0.5 ⁇ g/ml; and pepstatin (0.7 ⁇ g/ml) in the presence of octyl-beta-D-glucopyranoside (1%; Fisher Scientific, Fairlawn, N.J.) at 4° C. followed by eight hrs gentle rotation.
- a Branson Ultrasonics 250 Sonicator Branson Ultrasonics 250 Sonicator
- NaCl 0.1 M
- PMSF 0.002M
- leupeptin 0.5 ⁇ g/ml
- pepstatin 0.7 ⁇ g/ml
- components of the gels were transferred to nitrocellulose membranes (Novex) and subjected to immunoblotting employing rabbit anti-RAGE IgG (25 ⁇ g/ml) or rabbit anti-rat amphoterin IgG (25 ⁇ g/ml) as above. Binding of primary antibody was identified by employing horse radish peroxidase-conjugated goat anti-rabbit IgG (Sigma). In the case of tumor tissue, immunoblotting was performed using anti-p53 IgG (M-19) (Santa Cruz Biotechnology). Binding of primary antibody was identified by employing horse radish peroxidase-conjugated rabbit anti-goat IgG (Sigma).
- binding of secondary antibody was detected using ECL, chemiluminescence kit from Amersham Pharmacia Biotech (Piscataway, N.J.) according to the manufacturer's instructions.
- ECL chemiluminescence kit from Amersham Pharmacia Biotech (Piscataway, N.J.) according to the manufacturer's instructions.
- sRAGE-generating clones transfected tumor cells were plated onto tissue culture-treated plastic dishes containing 6 wells for 12 hrs in complete medium. At the end of that time, cells were washed and then incubated in medium without FBS for 24 hrs. Supernatant was then collected and subjected to SDS PAGE/immunoblotting as above. Densitometric analysis of band intensity was performed using Image Quant (Molecular Dynamics, Foster City, Calif.).
- C6 glioma tumors were removed from nude mice and fixed in formalin (10%). Paraffin-embedded tissue sections were prepared, each 5 ⁇ m thick. Assessment of apoptosis was made by TUNEL assay employing the In Situ Cell Death Detection kit (Boehringer Mannheim, Indianapolis, Ind.) according to the manufacturer's instructions.
- mice were injected subcutaneously into the dorsal midline of female NCR immunocompromised (nude) mice, age 4-6 weeks (Taconic Farms, ùGermantown, N.Y.). Where indicated, immediately after injection of tumor cells, mice received daily intraperitoneal injections of protein vehicle murine serum albumin (MSA), or the indicated concentration of murine sRAGE.
- MSA protein vehicle murine serum albumin
- Model of local tumor growth effect of blockade of amphoterin and/or RAGE. Wild-type rat C6 glioma cells were injected into the dorsal midline of female mice with severe combined immunodeficiency (SCID; Taconic Farms).
- mice were divided into four groups, each receiving intraperitoneal injection of the indicated F(ab′) 2 fragment every three days: the first received nonimmune rabbit F(ab′) 2 fragments (400 ⁇ g/dose); the second received rabbit anti-RAGE F(ab′) 2 fragments (200 ⁇ g/dose); the third received rabbit anti-amphoterin F(ab′) 2 fragments (200 ⁇ g/dose); and the fourth group received rabbit anti-RAGE F(ab′) 2 fragments (200 ⁇ g/dose)+anti-amphoterin F(ab′)2 fragments (200 ⁇ g/dose). Tumors were measured and all mice sacrificed on day 21.
- Murine corneal angiogenesis assay To determine if administration of murine soluble RAGE altered angiogenesis, a corneal micropocket angiogenesis assay was performed as described (O'Reilly et al., 1994). Briefly, pellets containing basic fibroblast growth factor (bFGF; Intergen, Purchase N.Y.) and sucralfate (Bukh Meditec, Denmark) were introduced into corneal pockets of male, 6-8 week old C57BL/6J mice. Mice received either intraperitoneal injection of murine serum albumin or murine soluble RAGE.
- bFGF basic fibroblast growth factor
- sucralfate Bovine serum albumin
- mice were sacrificed after S days treatment, and the eyes were examined under slit-lamp biomicroscopy (Nikon FS-2, Melville N.Y.) for angiogenic response.
- tumor cells were pretreated with the indicated concentration of nonimmune IgG, anti-RAGE IgG, anti-amphoterin IgG or anti-RAGE+anti-amphoterin IgG for one hr at 4° C. prior to placement in the Transwell chambers.
- concentration of nonimmune IgG, anti-RAGE IgG, anti-amphoterin IgG or anti-RAGE+anti-amphoterin IgG for one hr at 4° C. prior to placement in the Transwell chambers.
- cells remaining on the upper side of the filter were gently-removed by cotton swabbing.
- the bottom side of the filter was then fixed in methanol and stained with Giemsa (Sigma). Cells in 10 hpf were then counted. Migration assays on each of the four groups of transfected clones was performed similarly.
- Invasion assays were performed in an identical manner except that the upper chambers of the Transwell culture dishes were pretreated with Matrigel, 500 ⁇ g/filter (Becton Dickinson, Bedford Mass.) as previously described (Albini et al., 1987).
- Rat C6 glioma cells (2 ⁇ 10 5 in 0.2 ml medium) were placed onto the dried 3 H-collagen film and incubated at 37° C. in a humidified atmosphere (CO 2 , 5%). Cells were treated with either MSA (200 ⁇ g/ml) or sRAGE (100 ⁇ g/ml). At 1, 3, 6, 12 or 24 hrs, the culture supernatant was removed and mixed with solution containing ice-cold trichloroacetic acid (10%) and tannic acid (0.5%) (0.05 ml). After 30 mins incubation at 4° C., the mixture was subjected to centrifugation at 10,000 ⁇ g for 10 mins at 4° C. to precipitate undigested material. The radioactivity of the supernatant was measured in a liquid scintillation counter (LKB, Gaithersburg, Md.).
- Rat C6 glioma cells (2 ⁇ 10 5 cells/0.2 ml phenol-free medium) were placed into 96 well tissue culture-treated dishes. Cells were incubated in the presence of MSA (200 ⁇ g/ml) or sRAGE (100 ⁇ g/ml) in medium containing Spectrozyme PL (0.5M, American Diagnostica, Greenwich Conn.). At 1, 3, 6, 12 or 24 hrs, the plates were placed into a Bio Kinetics Reader (Bio Tek Instruments, Winooski Vt.) and A 405nm recorded.
- RNA derived from human tumors was generously provided by Dr. Benjamin Tycko, Columbia University Tumor Bank, Department of Pathology. Five micrograms of RNA were reverse transcribed with Superscript II (Life Technologies), according to the manufacturer's protocol. The following primers were employed for detection of transcripts for RAGE (5′-ACACTGCAGTCGGAGCTAAT-3′ (Seq. ID No. 7) and 5′-AAGATGACCCCAATGAGCAG-3′ (Seq. ID No. 8)) and for detection of amphoterin (5′-AAGAAGTGCTCAGAGAGGTG-31 (Seq. ID No. 9) and 5′-TAAGGCTGCTTGTCATCTGC-3′ (Seq. ID No. 10)).
- Conditions for PCR consisted of 40 amplification cycles employing 62° C. as the annealing temperature.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
- This application is a continuation-in-part application of U.S. Ser. No. 09/062,365, filed Apr. 17, 1998, the content of which is hereby incorporated by reference.
- The invention disclosed herein was made with Government support under National Institutes of Health Grant No. AG00602 HL60901, HL56881 and DK52496 from the Department of Health and Human Services and United States Public Health Service. Accordingly, the U.S. Government has certain rights in this invention.
- Throughout this application, various publications are referenced by author and date. Full citations for these publications may be found listed alphabetically at the end of the specification immediately preceding Sequence Listing and the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein.
- An important means by which tumors grow and invade surrounding normal tissue is by a complex series of cell-cell and cell matrix interactions. We have focused on the interaction of tumor cells with matrix-associated components. The Receptor to AGE (RAGE) interacts with a range of physiologically and pathophysiologically-relevant ligands (1-5). In normal developing neurons of the central nervous system, the expression of RAGE is markedly enhanced and co-localizes with that of its ligand, amphoterin. Amphoterin, a matrix-associated polypeptide, is expressed in developing neurons and certain tumor cells, such as rat C6 glioma cells (6-12).
- The present invention provides for a method for inhibiting tumor invasion or metastasis in a subject which comprises administering to the subject a therapeutically effective amount of a form of soluble Receptor for Advanced Glycation Endproducts (RAGE). The present invention also provides a method for evaluating the ability of an agent to inhibit tumor invasion in a local cellular environment which comprises: (a) admixing with cell culture media an effective amount of the agent; (b) contacting a tumor cell in cell culture with the media from step (a); (c) determining the amount of spreading of the tumor cell culture, and (d) comparing the amount of spreading of the tumor cell culture determined in step (c) with the amount determined in the absence of the agent, thus evaluating the ability of the agent to inhibit tumor invasion in the local cellular environment. The present invention also provides a pharmaceutical composition which comprises a therapeutically effective amount of the agent evaluated in the aforementioned method and a pharmaceutically acceptable carrier.
-
FIG. 1 . Transfection of C6 glioma cells with constructs expressing sRAGE results in diminished tumor volume compared with mock-transfected tumor cells. 1×105 tumor cells/ml (0.1 ml) were injected into the backs of nude mice. Cells were previously transfected either with constructs overexpressing sRAGE or mock-transfection (vector alone) as described above. At the indicated days after tumor injection, tumor volume was measured. The mean±standard error of the mean is reported. Twenty mice were studied per experimental group. Statistical considerations are indicated. This experiment was repeated three times with analogous results. -
FIG. 2 . The growth rate of sRAGE-transfected tumor cells is not different than that of mock-transfected tumor cells, in vivo. The rate of tumor cell growth was calculated and the slope of the line determined (±standard error) using Microsoft Excel. The y axis represents the natural logarithm of the tumor volume and the x axis represents time (days). These studies indicated that the slope of the growth curve for mock-transfected tumor cells was 0.247±0.025. For sRAGE-transfected tumor cells, the slope of the growth curve was 0.241±0.029. -
FIG. 3 . The rate of growth of sRAGE-transfected tumor cells is similar to that of mock-transfected tumor cells in in vitro studies. C6 glioma cells transfected with either sRAGE or mock were placed into 96 well tissue culture wells. On day three after onset of incubation, cells were fixed and stained and relative cell number assessed using the CYQUANT® assay from AMERSHAM®. These studies indicated that the relative cell number of sRAGE-transfected C6 cells on day three was 0.90±0.03 and 1.0±0.04 in mock-transfected C6 tumor cells (p=0.11). -
FIG. 4 . Systemic administration of sRAGE results in diminished tumor volume in C6 glioma cells injected into nude mice. C6 glioma cells (1×105/ml; 0.1 ml) were injected into the backs of nude mice. Immediately after injection, once daily injections of either mouse sRAGE (20 or 2 μg/day) or mouse serum albumin (MSA; 40 μg/day) were begun intraperitoneally. Tumor volume was measured ondays -
FIG. 5 . The rate of growth of C6 glioma cells is similar in sRAGE and MSA-treated mice in vivo. The rate of tumor cell growth was calculated and the slope of the line determined (±standard error) using Microsoft Excel. The y axis represents the natural logarithm of the tumor volume and the X axis represents time (days). The slope of the growth curve for C6 glioma tumor cells grown in the presence of mouse serum albumin was 0.264±0.03. The slopes of the growth curve for C6 glioma cells grown in the presence of sRAGE (20 vs. 2 μg/ml) were not different (0.311±0.04 and 0.313±0.04, respectively). -
FIG. 6 . The rate of growth of tumor cells is similar in the presence of either sRAGE or mouse serum albumin in in vitro studies. C6 glioma cells were placed into 96 well tissue culture wells and grown in the presence of either sRAGE (20 or 2 μg/ml) or mouse serum albumin (40 μg/ml). On day three after onset of incubation, cells were fixed and stained and relative cell number assessed using the CYQUANT® assay from AMERSHAM®. Relative cell number (day three) of cells treated with MSA was 1.0±0.045. Similarly, relative cell number in the presence of sRAGE (20 or 2 μg/ml) was 1.03±0.06 and 1.02±0.06, respectively. Statistical considerations are shown. -
FIG. 7 . RAGE and amphoterin are expressed in tumor cells (A); effect of stably-transfected RAGE/RAGE mutant rat C6 glioma cells (B-F); soluble RAGE (G); or anti-RAGE/amphoterin F(ab′)2 (H) in a model of local tumor growth and invasion. (A1-2). RAGE (1) and amphoterin (2) are expressed in tumor cells. Extracts of murine Lewis lung carcinoma cells (lane 2) and rat C6 glioma cells (lane 3) were prepared and subjected to SDS-PAGE and immunoblotting with anti-RAGE IgG (A1) or anti-amphoterin IgG (A2) as described. In A1, murine soluble recombinant RAGE (0.5 μg) was employed as positive control (lane 1); in A2, recombinant rat amphoterin (0.5 μg) was employed (lane 1). Molecular weight markers run simultaneously are indicated in the left margin (kDa). Controls employing preimmune rabbit IgG were negative (not shown). (B-F). Effect of stably-transfected RAGE/RAGE mutant C6 glioma cells implanted into immunocompromised (nude) mice. (B). The indicated clones of RAGE/RAGE mutant C6 glioma cells were injected in the dorsal midline of nude mice. Tumors were followed serially and mice sacrificed onday 21. Mean tumor volume (mm3)±standard error (SE) onday 21 is shown. Statistical considerations are as follows compared with mean tumor volume of three mock-transfected clones (pooled) (n=17): full-length RAGE (pooled) (n=18) vs mock, p<0.001; tail-deletion RAGE (pooled) (n=21) vs mock, p<0.01; and soluble RAGE (pooled) (n=18) vs mock, p<0.001. (C—F). Representative photographs of NCR nude mice-bearing mock (C) or RAGE/RAGE mutant C6 glioma clones onday 21 after implantation: (D) full-length RAGE, F2; (E) tail-deletion RAGE, T2; and (F), soluble RAGE, S1. F2, T2 and S1 refer to the particular clones as identified inFIG. 1A . (G). Effect of administration of soluble RAGE. Immediately upon injection of wild-type rat C6 glioma cells into the dorsal midline of NCR nude mice, the indicated doses of either murine sRAGE or murine serum albumin (MSA) were begun and continued daily until sacrifice,day 21. Mean tumor volume (=3) was measured ondays day 15. Mean tumor volume (mm3)±SE onday 21 is shown, n=7 per group. Statistical considerations are indicated in the figure. -
FIG. 8 . Blockade of RAGE suppresses distant metastasis. (A). Effect of administration of sRAGE on numbers of lung surface metastases. Murine Lewis lung murine carcinoma cells were injected into the dorsal midline of C57BL/6J mice. Onday 14, removal of primary tumor was performed. Three days prior to removal of primary tumor, mice received the indicated dose of sRAGE or MSA once daily by intraperitoneal injection until sacrifice, 21 days after removal of primary tumor. At that time, numbers of lung surface metastases were counted. Mean number of lung surface metastases±SE is shown, n=9 per group. (B-E). Representative photographs of lungs removed from C57BL/6J mice bearing metastatic Lewis lung carcinoma. (B) MSA, 200 μg IP/day; (C) sRAGE, 2 μg IP/day; (D)sRAGE 20 μg IP/day; and (E) sRAGE, 100 μg IP/day. (F-G). Representative sections from lung parenchyma were retrieved from C57BL/6J mice bearing metastatic Lewis lung carcinoma. Sections (5 μm thick) were fixed in formalin, embedded in paraffin and then subjected to staining with hematoxylin and eosin. (F) MSA, 200 μg IP/day; and (G) murine sRAGE, 100 μg IP/day. Magnification: ×2. -
FIG. 9 . Amphoterin/RAGE mediate tumor cell migration and invasion: in vitro analyses. (A). Effect of sRAGE on tumor cell proliferation in vitro. Wild-type rat C6 glioma cells were cultured in the presence of the indicated concentrations of MSA or murine sRAGE. Three days after plating, cell number was assessed using the CyQUANT cell proliferation assay as described. Mean number of cells SE in 16 wells is reported. Statistical considerations are indicated. (B). Effect of RAGE/RAGE mutation in clones of stably-transfected rat C6 glioma cells on tumor cell invasion. Invasion assays were performed as described employing three different clones of stably-transfected RAGE/RAGE mutant C6 glioma cells. The number of cells invading matrigel±SE in 10 high-powered fields (hpf) is reported. Statistical considerations are as follows compared with number of cells invading Matrigel from three mock-transfected clones (pooled): full-length RAGE (pooled) vs mock, p=<0.00001; tail-deletion RAGE (pooled) vs mock, p=<0.00001; and soluble RAGE (pooled) vs mock, p<0.00001. (C-D). Effect of RAGE/amphoterin blockade on tumor cell invasion. Invasion assays employing rat C6 glioma cells were performed in the presence of the indicated concentrations of MSA or sRAGE (C) or anti-RAGE/anti-amphoterin IgG (D). The number of cells invading matrigel±SE in 10 hpf is reported. Statistical considerations are indicated. (E). Effect of RAGE/RAGE mutation in clones of stably-transfected rat C6 glioma cells on tumor cell migration. Migration assays were performed as described employing three different clones of stably-transfected RAGE/RAGE mutant C6 glioma cells. The number of migrating cells±standard error in 10 hpf is reported. Statistical considerations are as follows compared with number of migrating cells from three mock-transfected clones (pooled): full-length RAGE (pooled) vs mock, p=<0.00001; tail-deletion RAGE (pooled) vs mock, p=<0.00001; and soluble RAGE (pooled) vs mock, p<0.00001. (F-G). Effect of RAGE/amphoterin blockade on tumor cell migration. Migration assays employing rat C6 glioma cells were performed in the presence or absence of the indicated concentrations of MSA or sRAGE (F) or anti-RAGE/anti-amphoterin IgG (G). The number of invading cells±SE in 10 hpf is reported. Statistical considerations are indicated. -
FIG. 10 . Lack of effect of RAGE blockade on tumor attachment (A), angiogenesis (B), collagenase (C) or plasmin (D) activity. (A). Attachment assay. Rat C6 glioma cells were employed in an in vitro assay of tumor attachment as described in the presence of sRAGE or MSA. At the indicated times, wells were depleted of medium by aspiration and washed twice. At each point, cell number per well was quantified using the CyQUANT assay kit. The mean % of cells attached compared with total number added ± SE of 16 wells is shown. No statistically-significant difference was observed between cells in the presence of MSA vs sRAGE (p>0.1). (B). Angiogenesis. Hydron pellets coated with basic FGF as described were implanted into the corneal pockets of C57BL/6J mice. Immediately after implantation, mice were treated once daily intraperitoneally with the indicated dose of MSA or sRAGE until sacrifice on day 5, n=8 per group. The eyes were then examined under slit-lamp biomicroscopy and area of angiogenic response calculated. Mean angiogenic area±SE is reported. Statistical considerations are indicated. (C). Assessment of collagenase activity. Activity of type IV collagenase was determined employing rat C6 glioma cells as described in the presence of the indicated concentrations of either MSA or sRAGE. Mean activity±SE is shown in 8 wells per group. At each time point, no statistically-significant difference was observed between cells in the presence of MSA vs sRAGE (p>0.2). (D). Assessment of plasmin activity. Activity of plasmin was determined employing rat C6 glioma cells as described in the presence of the indicated concentrations of either MSA or sRAGE. Mean plasmin activity SE is shown in 3 wells per group. At each time point, no statistically-significant difference was observed between cells in the presence of MSA vs sRAGE (p>0.1) - The present invention provides for a method for inhibiting tumor invasion or metastasis in a subject which comprises administering to the subject a therapeutically effective amount of a form of soluble Receptor for Advanced Glycation Endproducts (RAGE).
- As used herein, a “form of soluble RAGE” encompasses peptides which are derived from naturally occurring RAGE protein. The following are examples of forms of soluble RAGE: mature human soluble RAGE, mature bovine soluble RAGE, mature murine soluble RAGE, fragments or portions of a soluble RAGE. Representative peptides of the present invention include but are not limited to peptides having an amino acid sequence which corresponds to amino acid numbers (2-30), (5-35), (10-40), (15-45), (20-50), (25-55), (30-60), (30-65), (10-60), (8-100), 14-75), (24-80), (33-75), (45-110) of human sRAGE protein. In one embodiment the form of soluble RAGE may consist essentially of any such portion of the human RAGE peptide. In another embodiment, the form of soluble RAGE may consist essentially of a peptide which comprises any such portion of the human RAGE amino acid having the sequence from amino acid at position 1 (alanine) to amino acid number 332 (alanine) (without considering the 22 amino acid leader sequence).
- The abbreviations used herein for amino acids are those abbreviations which are conventionally used: A=Ala=Alanine; R=Arg=Arginine; N=Asn=Asparagine; D=Asp=Aspartic acid; C=Cys=Cysteine; Q=Gln=Glutamine; E=Glu=Gutamic acid; G=Gly=Glycine; H=His=Histidine; I=Ile=Isoleucine; L=Leu=Leucine; K=Lys=Lysine; M=Met=Methionine; F=Phe=Phenyalanine; P=Pro=Proline; S=Ser=Serine; T=Thr=Threonine; W=Trp=Tryptophan; Y=Tyr=Tyrosine; V=Val=Valine. The amino acids may be L- or D-amino acids. An amino acid may be replaced by a synthetic amino acid which is altered so as to increase the half-life of the peptide or to increase the potency of the peptide, or to increase the bioavailability of the peptide.
- In one embodiment the form of soluble RAGE comprises a peptide having the sequence from alanine at
position 1 to alanine at position 332 of human RAGE. - In another embodiment the form of soluble RAGE comprises a peptide of 10-40 amino acids having a sequence taken from within the sequence from alanine at
position 1 to alanine at position 332 of human RAGE. - In another embodiment, the form of soluble RAGE comprises a peptide having the following sequence of mature human RAGE.
- The following is the amino acid sequence of mature human RAGE (which does not include a 22 amino acid leader sequence):
-
(Seq I.D. No. 1) Ala Gln Asn Ile Thr Ala Arg Ile Gly Glu Pro Leu Val Leu Lys Cys Lys Gly Ala Pro Lys Lys Pro Pro Gln Arg Leu Glu Trp Lys Leu Asn Thr Gly Arg Thr Glu Ala Trp Lys Val Leu Ser Pro Gln Gly Gly Gly Pro Trp Asp Ser Val Ala Arg Val Leu Pro Asn Gly Ser Leu Phe Leu Pro Ala Val Gly Ile Gln Asp Glu Gly Ile Phe Arg Cys Gln Ala Met Asn Arg Asn Gly Lys Glu Thr Lys Ser Asn Tyr Arg Val Arg Val Tyr Gln Ile Pro Gly Lys Pro Glu Ile Val Asp Ser Ala Ser Glu Leu Thr Ala Gly Val Pro Asn Lys Val Gly Thr Cys Val Ser Glu Gly Ser Tyr Pro Ala Gly Thr Leu Ser Trp His Leu Asp Gly Lys Pro Leu Val Pro Asn Glu Lys Gly Val Ser Val Lys Glu Gln Thr Arg Arg His Pro Glu Thr Gly Leu Phe Thr Leu Gln Ser Glu Leu Met Val Thr Pro Ala Arg Gly Gly Asp Pro Arg Pro Thr Phe Ser Cys Ser Phe Ser Pro Gly Leu Pro Arg His Arg Ala Leu Arg Thr Ala Pro Ile Gln Pro Arg Val Trp Glu Pro Val Pro Leu Glu Glu Val Gln Leu Val Val Glu Pro Glu Gly Gly Ala Val Ala Pro Gly Gly Thr Val Thr Leu Thr Cys Glu Val Pro Ala Gln Pro Ser Pro Gln Ile His Trp Met Lys Asp Gly Val Pro Leu Pro Leu Pro Pro Ser Pro Val Leu Ile Leu Pro Glu Ile Gly Pro Gln Asp Gln Gly Thr Tyr Ser Cys Val Ala Thr His Ser Ser His Gly Pro Gln Glu Ser Arg Ala Val Ser Ile Ser Ile Ile Glu Pro Gly Glu Glu Gly Pro Thr Ala Gly Ser Val Gly Gly Ser Gly Leu Gly Thr Leu Ala Leu Ala Leu Gly Ile Leu Gly Gly Leu Gly Thr Ala. - In one embodiment the form of soluble RAGE comprises a V domain of naturally occurring soluble RAGE. In another embodiment the form of soluble RAGE comprises a C domain of naturally occurring soluble RAGE. The 22 amino acid leader sequence of immature human RAGE is Met Ala Ala Gly Thr Ala Val Gly Ala Trp Val Leu Val Leu Ser Leu Trp Gly Ala Val Val Gly (Seq. I.D. No. 2).
- In one embodiment the form of soluble RAGE is a peptide expressed by a replicable vector containing nucleic acid encoding the form of soluble RAGE. In one embodiment the form of soluble RAGE is a peptide which corresponds to all or part of soluble RAGE expressed by a replicable vector containing nucleic acid encoding the form of soluble RAGE.
- In another embodiment the replicable vector is capable of expressing the peptide within a tumor cell in a subject.
- In another embodiment the tumor cell is a eukaryotic cell.
- In another embodiment the replicable vector is a plasmid, an attenuated virus, a phage, a phagemid or a linear nucleic acid.
- In another embodiment, the method further comprises administering a pharmaceutically acceptable carrier to the subject during the administration of the form of soluble RAGE.
- In one embodiment the administration is via intralesional, intraperitoneal, intramuscular or intravenous injection; infusion; intrathecal administration; subcutaneous administration; liposome-mediated delivery; or topical, nasal, oral, ocular or otic delivery. As used herein, intrathecal administration includes administration in the cerebrospinal fluid by lumbar puncture.
- In one embodiment of the present invention, the subject is a mammal. In another embodiment, the mammal is a human.
- In one embodiment, the form of soluble RAGE is administered daily, weekly or monthly. The form of soluble RAGE may be delivered hourly, daily, weekly, monthly, yearly (e.g. in a time release form) or as a one time delivery. The delivery may be continuous delivery for a period of time, e.g. intravenous delivery. The agent or pharmaceutical composition of the present invention may be delivered intercranially or into the spinal fluid. In another embodiment, the therapeutically effective amount comprises a dose from about 0.000001 mg/kg body weight to about 100 mg/kg body weight. In a preferred embodiment, the therapeutically effective amount comprises a dose of from about 100 ng/day/kg body weight to about 200 mg/day/kg body weight.
- The present invention also provides a method for evaluating the ability of an agent to inhibit tumor invasion in a local cellular environment which comprises: (a) admixing with cell culture media an effective amount of the agent; (b) contacting a tumor cell in cell culture with the media from step (a); (c) determining the amount of spreading of the tumor cell culture, and (d) comparing the amount of spreading of the tumor cell culture determined in step (c) with the amount determined in the absence of the agent, thus evaluating the ability of the agent to inhibit tumor invasion in the local cellular environment.
- In one embodiment the tumor cell is a eukaryotic cell. In another embodiment the tumor cell is a cell of a subject. In a further embodiment, the subject is a human, a mouse, a rat, a dog or a non-human primate.
- In a further embodiment, the agent comprises a peptide, a peptidomimetic, a nucleic acid, a synthetic organic molecule, an inorganic molecule, a carbohydrate, a lipid, an antibody or fragment thereof, or a small molecule. The antibody may be a monoclonal antibody. The antibody may be a polyclonal antibody. In one embodiment, the fragment of the antibody comprises a Fab fragment. In another embodiment the fragment of the antibody comprises a complementarity determining region or a variable region. The agent may be conjugated to a carrier. The peptide or agent may be linked to an antibody, such as a Fab or a Fc fragment for specifically targeted delivery.
- In one embodiment the peptide is a synthetic peptide or a peptide analog. The peptide may be a non-natural peptide which has chirality not found in nature, i.e. D-amino acids or L-amino acids. In another embodiment the peptide comprises at least a portion of the sequence -Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-val-His-His-Gln-Lys-Leu-Val-Phe-phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val- (Seq. I.D. No. 3).
- In a further embodiment the peptide comprises at least a portion of the sequence -Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met- (Seq. I.D. No. 4). In another embodiment the peptide has the amino acid sequence A-Q-N-I-T-A-R-I-G-E-P-L-V-L-K-C-K-G-A-P-K-K-P-P-Q-R-L-E-W-K (Seq. I.D. No. 5).
- In another embodiment the peptide has the amino acid sequence A-Q-N-I-T-A-R-I-G-E (Seq. I.D. No. 6).
- In addition to naturally-occurring forms of soluble RAGE, the present invention also embraces other peptides such as peptide analogs of sRAGE. Such analogs include fragments of sRAGE. Following the procedures of the published application by Alton et al. (WO 83/04053), one can readily design and manufacture genes coding for microbial expression of peptides having primary conformations which differ from that herein specified for in terms of the identity or location of one or more residues (e.g., substitutions, terminal and intermediate additions and deletions). Alternately, modifications of cDNA and genomic genes can be readily accomplished by well-known site-directed mutagenesis techniques and employed to generate analogs and derivatives of sRAGE polypeptide. Such products share at least one of the biological properties of sRAGE but may differ in others. As examples, products of the invention include those which are foreshortened by e.g., deletions; or those which are more stable to hydrolysis (and, therefore, may have more pronounced or longerlasting effects than naturally-occurring); or which have been altered to delete or to add one or more potential sites for O-glycosylation and/or N-glycosylation or which have one or more cysteine residues deleted or replaced by e.g., alanine or serine residues and are potentially more easily isolated in active form from microbial systems; or which have one or more tyrosine residues replaced by phenylalanine and bind more or less readily to target proteins or to receptors on target cells. Also comprehended are polypeptide fragments duplicating only a part of the continuous amino acid sequence or secondary conformations within sRAGE, which fragments may possess one property of sRAGE and not others. It is noteworthy that activity is not necessary for any one or more of the polypeptides of the invention to have therapeutic utility or utility in other contexts, such as in assays of sRAGE antagonism. Competitive antagonists may be quite useful in, for example, cases of overproduction of sRAGE.
- The agent of the present invention may be a peptidomimetic which may be at least partially unnatural. The agent may be a small molecule mimic of a portion of the amino acid sequence of sRAGE. The agent may have increased stability, efficacy, potency and bioavailability by virtue of the mimic. Further, the agent may have decreased toxicity. The peptidomimetic agent may have enhanced mucosal intestinal permeability. The agent may be synthetically prepared. The agent of the present invention may include L-,D-, DL- or unnatural amino acids, alpha, alpha-disubstituted amino acids, N-alkyl amino acids, lactic acid (an isoelectronic analog of alanine). The peptide backbone of the agent may have at least one bond replaced with PSI—[CH═CH] (Kempf et al. 1991). The agent may further include trifluorotyrosine, p-Cl-phenylalanine, p-Br-phenylalanine, poly-L-propargylglycine, poly-D,L-allyl glycine, or poly-L-allyl glycine. Examples of unnatural amino acids which may be suitable amino acid mimics include β-alanine, L-α-amino butyric acid, L-γ-amino butyric acid, L-α-amino isobutyric acid, L-ε-amino caproic acid, 7-amino heptanoic acid, L-aspartic acid, L-glutamic acid, cysteine (acetamindomethyl), N-ε-Boc-N-α-CBZ-L-lysine, N-ε-Boc-N-α-Fmoc-L-lysine, L-methionine sulfone, L-norleucine, L-norvaline, N-α-Boc-N-δCBZ-L-ornithine, N-δ-Boc-N-α-CBZ-L-ornithine, Boc-p-nitro-L-phenylalanine, Boc-hydroxyproline, Boc-L-thioproline. (Blondelle, et al. 1994; Pinilla, et al. 1995).
- In one embodiment of the present invention the agent is a form of soluble human RAGE. In another embodiment the agent is an extracellular portion human RAGE. In another embodiment the agent inhibits an interaction between the tumor cell and an extracellular matrix molecule. In one embodiment the extracellular matrix molecule is a laminin, a fibronectin, amphoterin, a cadherin, an integrin or a hyaluronic acid. In another embodiment the integrin is an αVβV integrin, an αVβIII integrin, or an αIβIII integrin. In another embodiment, the laminin is β1 laminin. In another embodiment the agent inhibits binding of RAGE to amphoterin.
- The present invention also provides a pharmaceutical composition which comprises a therapeutically effective amount of the agent evaluated in the aforementioned method and a pharmaceutically acceptable carrier. In one embodiment the carrier is a diluent, an aerosol, a topical carrier, an aqueous solution, a replicable nucleic acid vector, a liposome, a magnetic bead, a nonaqueous solution or a solid carrier.
- The actual effective amount will be based upon the size of the subject. The biodegradability of the agent, the bioactivity of the agent and the bioavailability of the agent are factors which will alter the effective amount. The agent may be delivered topically in a cream or salve carrier. It may be reapplied as needed based upon the adsorbancy of the carrier to the skin or mucosa or wound. If the agent does not degrade quickly, is bioavailable and highly active, a smaller amount will be required to be effective. The effective amount will be known to one of skill in the art; it will also be dependent upon the form of the agent, the size of the agent and the bioactivity of the agent. One of skill in the art could routinely perform empirical activity tests for a agent to determine the bioactivity in bioassays and thus determine the effective amount.
- The present invention also provides a method for inhibiting tumor invasion or metastasis in a subject which comprises administering to the subject a therapeutically effective amount of the aforementioned pharmaceutical composition.
- One embodiment of the present invention is a composition which comprises a form of soluble RAGE and a pharmaceutically acceptable carrier. In another embodiment the invention provides a composition which comprises the aforementioned agent and a pharmaceutically acceptable carrier.
- As used herein, the term “pharmaceutically acceptable carrier” encompasses any of the standard pharmaceutically accepted carriers, such as phosphate buffered saline solution, acetate buffered saline solution (a likely vehicle for parenteral administration), water, emulsions such as an oil/water emulsion or a triglyceride emulsion, various types of wetting agents, tablets, coated tablets and capsules. An example of an acceptable triglyceride emulsion useful in intravenous and intraperitoneal administration of the compounds is the triglyceride emulsion commercially known as Intralipid®.
- When administered orally or topically, such agents and pharmaceutical compositions would be delivered using different carriers. Typically such carriers contain excipients such as starch, milk, sugar, certain types of clay, gelatin, stearic acid, talc, vegetable fats or oils, gums, glycols, or other known excipients. Such carriers may also include flavor and color additives or other ingredients. The specific carrier would need to be selected based upon the desired method of deliver, e.g., PBS could be used for intravenous or systemic delivery and vegetable fats, creams, salves, ointments or gels may be used for topical delivery.
- Such compositions are liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (e.g., Tris-HCl., acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.g.,
Tween 20,Tween 80, pluronic F68, bile acid salts), solubilizing agents (e.g., glycerol, polyethylene glycerol), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (e.g., lactose, mannitol), covalent attachment of polymers such as polyethylene glycol to the agent, complexation with metal ions, or incorporation of the agent into or onto particulate preparations of polymeric agents such as polylactic acid, polglycolic acid, hydrogels, etc, or onto liposomes, micro emulsion's, micelles, unilamellar or multi lamellar vesicles, erythrocyte ghosts, or spheroplasts. Such compositions will influence the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance of the agent or composition. The choice of compositions will depend on the physical and chemical properties of the agent. - The agent of the present invention may be delivered locally via a capsule which allows sustained release of the agent or the peptide over a period of time. Controlled or sustained release compositions include formulation in lipophilic depots (e.g., fatty acids, waxes, oils). Also comprehended by the invention are particulate compositions coated with polymers (e.g., poloxamers or poloxamines) and the agent coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to ligands of tissue-specific receptors. Other embodiments of the compositions of the invention incorporate particulate forms protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal and oral.
- When administered, agents (such as a peptide comprising the V-domain of sRAGE) are often cleared rapidly from the circulation and may therefore elicit relatively short-lived pharmacological activity. Consequently, frequent injections of relatively large doses of bioactive agents may by required to sustain therapeutic efficacy. Agents modified by the covalent attachment of water-soluble polymers such as polyethylene glycol, copolymers of polyethylene glycol and polypropylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone or polyproline are known to exhibit substantially longer half-lives in blood following intravenous injection than do the corresponding unmodified agents (Abuchowski et al., 1981; Newmark et al., 1982; and Katre et al., 1987). Such modifications may also increase the agent's solubility in aqueous solution, eliminate aggregation, enhance the physical and chemical stability of the agent, and greatly reduce the immunogenicity and reactivity of the agent. As a result, the desired in vivo biological activity may be achieved by the administration of such polymer-agent adducts less frequently or in lower doses than with the unmodified agent.
- Attachment of polyethylene glycol (PEG) to agents is particularly useful because PEG has very low toxicity in mammals (Carpenter et al., 1971). For example, a PEG adduct of adenosine deaminase was approved in the United States for use in humans for the treatment of severe combined immunodeficiency syndrome. A second advantage afforded by the conjugation of PEG is that of effectively reducing the immunogenicity and antigenicity of heterologous compounds. For example, a PEG adduct of a human protein might be useful for the treatment of disease in other mammalian species without the risk of triggering a severe immune response. The agent of the present invention may be delivered in a microencapsulation device so as to reduce or prevent an host immune response against the agent or against cells which may produce the compound. The agent of the present invention may also be delivered microencapsulated in a membrane, such as a liposome.
- Polymers such as PEG may be conveniently attached to one or more reactive amino acid residues in a protein such as the alpha-amino group of the amino terminal amino acid, the epsilon amino groups of lysine side chains, the sulfhydryl groups of cysteine side chains, the carboxyl groups of aspartyl and glutamyl side chains, the alpha-carboxyl group of the carboxy-terminal amino acid, tyrosine side chains, or to activated derivatives of glycosyl chains attached to certain asparagine, serine or threonine residues.
- Numerous activated forms of PEG suitable for direct reaction with proteins have been described. Useful PEG reagents for reaction with protein amino groups include active esters of carboxylic acid or carbonate derivatives, particularly those in which the leaving groups are N-hydroxysuccinimide, p-nitrophenol, imidazole or 1-hydroxy-2-nitrobenzene-4-sulfonate. PEG derivatives containing maleimido or haloacetyl groups are useful reagents for the modification of protein free sulfhydryl groups. Likewise, PEG reagents containing amino hydrazine or hydrazide groups are useful for reaction with aldehydes generated by periodate oxidation of carbohydrate groups in proteins.
- This invention is illustrated in the Experimental Details section which follows. These sections are set forth to aid in an understanding of the invention but are not intended to, and should not be construed to, limit in any way the invention as set forth in the claims which follow thereafter.
- An important means by which tumors grow and invade surrounding normal tissue is by a complex series of cell-cell and cell matrix interactions. We have focused on the interaction of tumor cells with matrix-associated components. The Receptor to AGE (RAGE) interacts with a range of physiologically and pathophysiologically-relevant ligands (1-5). In normal developing neurons of the central nervous system, the expression of RAGE is markedly enhanced and co-localizes with that of its ligand, amphoterin.
- Amphoterin, a matrix-associated polypeptide, is expressed in developing neurons and certain tumor cells, such as rat C6 glioma cells (6-12).
- In in vitro experiments, the interaction of neuronal RAGE with amphoterin mediates neurite outgrowth: on amphoterin-coated matrices, neurite outgrowth is inhibited in the presence of either anti-RAGE (Fab)2 or soluble RAGE (sRAGE; the extracellular two thirds of RAGE). In contrast, blocking access to RAGE had no effect on neurite outgrowth on laminin- or poly-lysine-coated matrices. As in the case of amphoterin, the expression of RAGE decreases after birth in developing rats. Notably, however, the expression of amphoterin is also increased in tumor cells. It has been postulated that in that context, amphoterin may effect matrix degradation by activation of plasminogen: events critical in the ability of tumors to locally invade their immediate environment. Indeed, the ability of tumors to modulate local tissue and vasculature is essential for distal invasion and the development of metastases.
- In our studies, we tested the hypothesis that blockade of tumor cell RAGE would interfere with the ability of tumors to compromise the integrity of their local environment, at least in part by disruption of the RAGE (cellular)-amphoterin (matrix) interaction. We demonstrate here that when C6 (rat) glioma cells were transfected with constructs designed to overexpress soluble RAGE (SRAGE) in the local tumor environment, tumor growth was significantly diminished in nude mice. In contrast, mock transfection of C6 glioma cells (vector only) had no effect on tumor growth compared with untreated cells. Similarly, when C6 glioma cells were injected into nude mice, intraperitoneal administration of sRAGE resulted in dose-dependent diminution of tumor size. In contrast, treatment with mouse serum albumin was without effect.
- Taken together, our studies indicate that administration of sRAGE may be an important means by which to limit tumor growth in the local environment and, likely, the development of distant metastases. Our studies indicate that interruption of cell (RAGE)-matrix (amphoterin and/or similar structures) is at least one mechanism by which sRAGE limits tumor growth. Our data strongly suggest, however, that sRAGE does not affect the rate of tumor cell growth.
- These studies indicate that RAGE may be a novel target for the prevention of local tumor growth and invasion. Soluble RAGE (sRAGE) may thus represent a model structure for the development of agents to limit tumor growth and invasion into the local environment, and, potentially, the development of distant metastases.
- Cell culture. C6 glioma cells (rat) we obtained from the American Type Tissue Corporation (ATCC, Rockville, Md.) and characterized as previously described (Singh et al, 1997). Cells were grown as recommended by the ATCC. Transfection of constructs expressing either human soluble RAGE (Neeper et al., 1992) were prepared and transfected into C6 glioma cells using LipoFECTAMINE® (Life Technologies, Grand Island, N.Y.). Stable lines were selected using G418 (Life Technologies). Constructs containing vector alone (mock) were transfected into C6 cells as controls.
- Animal studies. NCR nude mice were obtained from Taconic Laboratories. At the age of 8-10 weeks, C6 glioma cells (usually about 105 cells/ml) were injected into the lower backs of the mice. Tumor volume was measured sequentially and recorded. At sacrifice, mice were deeply anesthetized and then tumors removed and weighed.
- Preparation of Mouse Soluble Rage. Murine Soluble Rage was prepared using a baculovirus-Sf9 cell expression system. Murine sRAGE was purified from cellular supernatant using FPLC Mono S® (Amersham-Pharmacia®) and endotoxin removed using De-Toxigel® columns (Pierce, Rockford, Ill.). The final product was pure based on SDS-PAGE electrophoresis (nonreducing conditions). No detectable endotoxin was found in the final samples (limulus amebocyte assay. Sigma Chemical Co., St. Louis, Mo.). Control mice were treated with mouse serum albumin (MSA: Sigma Chemical Co.)
- Injection of sRAGE into mice. Mice were treated immediately upon injection of the tumor cells into the back of the mouse with the indicated dose of sRAGE or mouse serum albumin (equimolar concentration) through the day of sacrifice. Protein was injected intraperitoneally in a volume of 0.1 ml in phosphate-buffered saline.
- Quantitation of cell number. C6 glioma cells were grown onto the wells of 96-well plates. On day, cells were fixed and relative cell number determined using the CYQUANT® assay system from Amersham.
- We first determined by RT-PCR that C6 glioma cells expressed mRNA for RAGE; the presence of RAGE antigen was confirmed by immunohistochemistry. In order to determine if sRAGE might interrupt tumor growth and invasion, we performed two sets of experiments. In the first, C6 glioma cells were transfected with constructs to express either sRAGE or vector alone. In other experiments, C6 glioma cells were injected into nude mice; tumors were generated, and then mice were treated parenterally with either sRAGE or mouse serum albumin.
- sRAGE-Transfected C6 Glioma Cells.
- sRAGE-transfected or mock-transfected C6 glioma cells were injected into nude mice and tumor volume sequentially measured. When tumor volume was measure on
days FIG. 1 ). Onday 14, mean tumor volume in nude mice injected with mock-transfected tumors was 315,276.5±3,790.4 μm3 vs 27,875.4±4,199.6 μm3 mean tumor volume in sRAGE-transfected tumor (11.3-fold difference; p<0.00005). Onday 17, mean tumor volume in nude mice injected with mock-transfected tumor was 823,759±142,841.5 μm3 vs. 50,645±5,109.7 μm3 (16.2-fold difference; p<0.00005). Onday 21, mean tumor volume in nude mice injected with mock-transfected tumor was 2,200,000±420,235 μm3 vs. 152,000±22,487.3 μm3 (14.5-fold difference; p=0.00001). When evaluated by ELISA, an at least three-fold increase in levels of sRAGE were found in sRAGE-transfected tumors vs. Those transfected with vector alone (mock). Histologic analysis confirmed markedly smaller tumors, with evidence of necrosis. - The growth rate of the transfected tumor cells (sRAGE and mock) derived from analysis of the above in vivo data revealed that there was no difference between the rate of growth of sRAGE-transfected C6 glioma cells compare with those mock-transfected (
FIG. 2 ). When the natural log of tumor volume was plotted vs time, the slope of the growth curve for mock-transfected tumor cells the slope of the growth curve was 0.241±0.025. These data are consistent with the concept that sRAGE does not alter cellular replication. Rather, they suggest that the interaction of tumor cells with their local environment is affected in a manner inconsistent with their local spread and invasion. - To further confirm that transfection of sRAGE into C6 glioma cells did not alter the rate of tumor growth, we demonstrated that when sRAGE-transfected or mock transfected C6 glioma cells were grown in culture, no difference in the cell number was observed at three days incubation (
FIG. 3 ). Using a colormetric assay system from Amersham for quantitation of cell number, on day three, relative cell number of sRAGE-transfected C6 cells was 0.90±0.03 vs. 1.0±0.04 in mock-transfected C6 tumor cells (p=0.11). These data were further suggestive of the importance of sRAGE in limiting tumor cell growth and spread into the local tumor environment in vivo and suggest that sRAGE does not impact on cellular replication processes. - Systemic Administration of sRAGE.
- In order to further delineate the role of sRAGE in limiting tumor growth and invasion into the local environment, C6 tumors were established in NCR nude mice by injection of 105 cells/ml (0.1 ml) C6 glioma cells (without transfection). Immediately after injection of tumor cells, intraperitoneal administration of sRAGE was begun (either 20 or 2 μg/day) or mouse serum albumin (
FIG. 4 ). Onday 14, mean tumor volume in MSA-treated mice was 459,000±87,457.6 μm3. In mice treated with sRAGE, 20 μg/day, however, mean tumor volume was decreased 2-fold (225,000±38,054 μm3; p=0.03). In contrast, mice treated with sRAGE, 2 μg/day, demonstrated no significant change in tumor volume (305,000±79,998; p=0.21 [when compared with those treated with MSA]}. Onday 17, mean tumor volume in MSA-treated mice was 935,000±117,499 μm3. In contrast, mice treated with sRAGE, 2 μg/day, demonstrated no significant change in tumor volume (637,000±127,698 μm3; p=0.22 [when compared with those treated with MSA]). - When the growth rate of the tumor cells was plotted, no apparent differences were noted among tumors in mice treated with sRAGE (both doses) or mouse serum albumin (
FIG. 5 ). When the natural log of the tumor volume was plotted vs. time, the slope of the growth curve for C6 glioma tumor cells grown in the presence of mouse serum albumin was 0.264±0.03. The slopes of the growth curve for C6 glioma cells grown in the presence of sRAGE (20 vs. 2 μg/ml) were not different (0.311±0.04 and 0.313±0.04, respectively). These data further support the hypothesis that sRAGE does not impact on cellular replication; rather, sRAGE appears to inhibit cellular interaction with matrix components that is necessary for tumor impingement in the local environment. - Finally, when C6 cells were cultured in the presence of sRAGE (high and low doses; 20 and 2 μg/ml) or mouse serum albumin, no apparent difference in relative cell number was observed (
FIG. 6 ). Relative cell number (day three) of cells treated with MSA was 1.0±0.045. Similarly, relative cell number in the presence of sRAGE (20 or 2 μg/ml) was 1.03±0.06 and 1.02±0.06, respectively. These data further support the concept that sRAGE does not impact upon cellular proliferation; rather, it more likely affects the ability of tumor cells in vivo to grow and extend into their local environment. - A number of factors have been suggested to be important in the ability of tumors to grow and invade their local environment. Central to these involves processes such as angiogenesis, the ability of the tumors to develop tumor-specific vasculature; matrix degradation, in which the ability of matrix metalloproteinases (MMPs) to degrade the surrounding matrix is critical for the local spread and invasiveness of tumors; inhibition of the action of tissue inhibitors of metalloproteinases (TIMPs), whose natural function is to inhibit the activity of MMPs; and integrin-cell/integrin/matrix interactions, reactions in which specific ligand-receptor contact initiates signaling cascades that eventuate in tumor spread (14-25).
- Certainly, a multitude of factors have been postulated to result in local tumor growth and invasion. In the present studies, the ability of sRAGE to result in diminished tumor volume appears to result not from a direct effect of sRAGE on cellular replication processes. Rather, the interaction of tumor cells with their local environment appears hampered. We postulated that perhaps one means by which this occurs is by inhibition of the tumor RAGE-matrix amphoterin components. Amphoterin and likely related structures have been suggested to activate plasminogen, thereby effecting one means by which, for example, MMPs may be activated in the tumor environment. It is quite possible, however, that additional, as yet unidentified mechanisms exist by which sRAGE exerts beneficial effects in this model.
- A current focus of this work is to study the effects of sRAGE in a model of tumor metastases and distal invasion. At this time, studies are underway utilizing Lewis lung carcinoma cells; a model in which distant invasion of the tumor into the pleura and lung parenchyma ensues after removal of the primary lesion (placed onto the lower back of the mice).
- In conclusion, while precise mechanisms underlying the beneficial effects of sRAGE are under study in this model of local tumor growth, our data suggest that sRAGE may represent a novel structure in the design of agents to limit tumor spread and invasion. In this context, sRAGE may also exert beneficial effects in the prevention of tumor distal growth and metastases.
-
- 1. Schmidt, A-M., et al. J. Biol. Chem. 276: 14987-14997, 1992.
- 2. Neeper, M., et al. J. Biol. Chem. 267: 14998-15004, 1992.
- 3. Hori, O., et al. J. Biol. Chem. 170: 25752-25761, 1995.
- 4. Yan, S. D., et al. Nature 382: 685-691, 1996.
- 5. Yan, S. D., et al. Proc. Natl. Acad. Sci. 94: 5296-5301, 1997.
- 6. Schmidt, A-M., et al. In Hormones and Signalling, Volume I, Academic Press, p. 41-63, 1997.
- 7. Rauvala, H. and Pihlaskari, R. J. Biol. Chem. 262: 16625-16635, 1987.
- 8. Merenmies, J., et al. J. Biol. Chem. 266: 16722-16729, 1991.
- 9. Salmivirta, M., et al. Exp. Cell Res. 200: 444-451, 1992.
- 10. Mohan, P S, J., et al. Biol. And Biophyx. Res. Comm. 182: 689-696, 1992.
- 11. Parkkinen, J., J. Biol. Chem. 268: 19726-19738, 1993.
- 12. Parkkinen, J. and H. Rauvala. J. Biol. Chem. 266: 16730-16735, 1991.
- 13. Singh, S. P., et al. Neuroreport 8: 2359-2363, 1997.
- 14. Price, J. T., et al. Critical Reviews in Biochemistry and Molecular Biology. 32: 175-253, 1997.
- 15. Timar, J., et al. Anticancer Research 16(6A): 3299-3306, 1997.
- 16. DeVries, T J, et al. Pathology, Research and Practice 192: 718-733, 1996.
- 17. Kubota, S., et al. International J. Cancer 70: 106-111, 1997.
- 18. Powell, W C and L M Matrisian. Current Topics in Microbiology and Immunology 213:1-21, 1996.
- 19. Seiki, M. Current Topics in Microbiology and Immunology 213: 23-32, 1996.
- 20. Byers S W, C L Sommers, B. Hoxter, A M Mercurio and A J Tozeren. Cell Science 108: 2053-2064, 1995.
- 21. Yoneda, J., et al. Experimental Cell Research 217: 169-179, 1995.
- 22. Tsang, T C, et al. Cancer Research 54: 882-886, 1994.
- 23. Grant D S, et al. Pathology, Research and Practice. 190: 854-863, 1994.
- 24. Spiegel, S., et al. Breast Cancer Research and Treatment 312: 337-348, 1994.
- 25. Thorgeirsson, U P, et al. J. Neuro-Oncology 18: 89-103, 1993.
- Receptor for AGE (RAGE), a multiligand member of the immunoglobulin superfamily of cell surface molecules, interacts with distinct ligands implicated in development and pathophysiological processes. Previous studies linking RAGE to neurite outgrowth, via ligation of amphoterin, suggested its possible contribution to cellular migration and invasiveness. As high levels of amphoterin and RAGE are present during early neuronal development and in tumors, the impact of the RAGE-amphoterin axis on tumor progression was assessed. Blockade of RAGE-amphoterin interaction potently suppressed primary tumors grown from implanted rat C6 glioma cells, and lung metastases in mice bearing Lewis lung carcinoma. Blockade of RAGE and amphoterin inhibited tumor cell invasion and migration, though proliferation, angiogenesis, matrix attachment and cellular proteolytic (collagenolytic or plasmin) activity were unchanged. These findings highlight a novel paradigm in tumor biology and identify RAGE-amphoterin interaction as an unique target for therapeutic strategies to interrupt both local tumor growth and distant metastasis, whose effects are likely to complement other anti-tumor strategies.
- The Receptor for Advanced Glycation Endproducts (RAGE), a multiligand member of the immunoglobulin superfamily of cell surface molecules (Schmidt et al., 1992; Neeper et al., 1992), interacts with distinct ligands implicated in development and homeostasis (Hori et al., 1995), as well as in certain pathophysiologic situations, such as diabetes, Alzheimer's disease and inflammation (Park et al., 1998; Wautier et al., 1996; Yan et al., 1996; Yan et al., 1997 and Hofmann et al., 1998). RAGE was first identified as a signal transduction receptor for products of nonenzymatic glycation and oxidation of proteins/lipids, the Advanced Glycation Endproducts, or AGEs, whose accumulation in disorders such as diabetes has been linked to the pathogenesis of vascular and inflammatory cell complications (Brownlee et al., 1988; and Sell and Monnier, 1989). Subsequent studies identified RAGE as a neuronal/microglial interaction site for amyloid-beta peptide (Aβ) (Yan et al., 1996; Yan et al., 1997), the proteolytic cleavage product of beta-amyloid precursor protein, whose accumulation in Alzheimer disease brain has been linked to inflammation and neuronal toxicity (Selkoe, 1994; Sisodia and Price, 1995). More recently, we have identified EN-RAGE (Extracellular Novel RAGE binding protein) (Hofmann, et al., 1998), and related members of the S100/calgranulin family of proinflammatory cytokines (Schafer and Heinzmann, 1996; and Zimmer, et al., 1995), as ligands for RAGE. Interaction of EN-RAGEs with RAGE triggers proinflammatory pathways in endothelial cells, macrophages and lymphocytes. Blockade of RAGE suppressed the immune/inflammatory response in murine models of delayed-type hypersensitivity (DTH) and colitis (Hofmann, et al., 1998). In these settings, engagement of RAGE by AGES, Aβ, and EN-RAGEs recruits and activates key cell signalling pathways, such as p21ras, MAP kinases, and NF-KB (Yan et al., 1994 and Lander et al., 1997), thereby globally reprogramming cellular functions.
- These findings focused attention on RAGE as an integral participant in the cellular response to pathophysiologic stimuli. However, such an immunoglobulin superfamily receptor was unlikely to have evolved solely to mediate interaction with pathologic ligands, suggesting a possible unexplored aspect of the biology of RAGE in development and/or homeostasis. In this context, we previously identified RAGE as a cellular receptor for amphoterin (Hori, et al., 1995), a polypeptide linked to neurite outgrowth in cultured cortical neurons (Rauvala and Pihlaskari, 1987; Rauvala et al., 1988; Parkkinen and Rauvala, 1991; and Parkkinen et al., 1993). Engagement of immobilized amphoterin by cell surface neuronal RAGE promoted neurite outgrowth (Hori, et al., 1995). Furthermore, the striking colocalization of RAGE and amphoterin in developing neurons of the central nervous system, especially at the leading edge of advancing neurites, suggested a possible contribution of RAGE-amphoterin interaction to cellular migration and, in other settings, invasiveness. High levels of amphoterin (Parkkinen et al., 1993) and RAGE (see below) in a range of transformed cells highlighted the possibility that amphoterin interaction with RAGE in transformed cells was likely to occur. These considerations led us to hypothesize that amphoterin-mediated activation of RAGE might represent a novel mechanism promoting tumor cell migration and invasion, potentially impacting on local growth and distant spread of malignancies.
- RAGE-amphoterin interaction as a mediator of local tumor growth. Rat C6 glioma cells (Benda et al, 1968; Parkkinen et al., 1993) provided an ideal starting point to test our hypothesis. Immunoblotting of C6 glioma cell lysates showed expression of both RAGE (FIG. 7A1, lane 3), as demonstrated by the =45 kDa band identified with anti-RAGE IgG, and amphoterin, as shown by the ≈29 kDa band seen with anti-amphoterin IgG (FIG. 7A2, lane 3). Immunohistochemistry employing nonpermeabilized C6 glioma cells indicated that both RAGE and amphoterin were present on the cell surface.
- The extracellular region of RAGE is composed of one V-type followed by two “C”-type immunoglobulin-like domains, and comprises the soluble, ligand-bearing portion of the receptor (Neeper et al., 1992). Following the extracellular and hydrophobic transmembrane spanning domains is a short, highly-charged cytosolic tail. Recent studies have shown the cytosolic tail of the receptor to be essential for RAGE-dependent intracellular signalling and subsequent cellular activation (Fu et al., 1998; Hofmann et al., 1998). Thus, two strategies for blocking PAGE-mediated cellular stimulation are: 1) expression of a RAGE mutant devoid of the cytosolic tail, producing a truncated form of the receptor present on the cell surface and competent for ligand binding, but one which exerts a dominant-negative effect with respect to RAGE signalling; and, 2) expression of a truncated soluble (s) form of RAGE comprising only the extracellular domain termed sRAGE, which binds up RAGE ligands preventing their access to the cell surface receptor. Stably-transfected clones of C6 glioma cells were produced overexpressing either full-length RAGE (F), the tail-deletion RAGE mutant (T) or sRAGE (S) (Table 1).
-
TABLE 1 Series of stably-transfected clones expressing full-length RAGE (F); cytosolic tail-deletion RAGE (T); soluble RAGE (S); or mock control (vector alone; M). RAGE Expression, fold increase Natural log tumor in densitometry units; F, T or volume/day vs time; Clone S-transfectants vs M mean ± standard error M1 1.0 0.25 ± 0.07 M2 1.0 0.30 ± 0.06 M3 1.0 0.25 ± 0.14 F1 11.7 0.32 ± 0.06 F2 9.0 0.37 ± 0.06 F3 22.6 0.27 ± 0.04 T1 20.2 0.42 ± 0.03 T2 7.7 0.39 ± 0.03 T3 9.4 0.33 ± 0.04 S1 3.4 0.16 ± 0.09 S2 7.0 0.43 ± 0.03 S3 8.4 0.30 ± 0.09
compared with mock transfected clones, no significant differences were observed in slope values among F1, F2, or F3 vs M; T1, T2 or T3 vs M; S1, S2, or S3 vs M; in each case, p>0.05. - Three independent clones of each of the rat C6 glioma transfectants, as well as mock-transfected C6 glioma cells (designated M), were implanted into immunocompromised (nude) mice in order to evaluate tumor growth. Compared with mock-transfected tumor cells (FIG. 7B,c), an ≈5-fold increased tumor volume was observed in cells overexpressing full-length RAGE (FIG. 7B,D) (598±113 vs 3,006±573 mm3, respectively; p<0.001) (
FIG. 7B ). Consistent with a role for RAGE signalling in mediating the receptor's effect on tumor behavior, tumor volume was decreased ≈3-fold (196±31 mm3) in tumors derived from C6 glioma cell clones transfected with the tail-deletion mutant (FIG. 7B,C) (p<0.01). Further support for a role of RAGE-mediated cellular activation in modulating tumor cell phenotype was emphasized by the ≈6.5-fold (93±23 mm3) suppression of tumor volume observed in neoplasms derived from sRAGE-transfected C6 glioma cells (FIG. 7B , F) (p<0.001). To be certain that elevated levels of sRAGE in the tumor microenvironment were responsible for its effect on cells, rather than some unusual property of sRAGE produced by the neoplasm itself, soluble receptor was administered once daily to nude mice immediately upon injection of rat C6 glioma cells (Wautier et al., 1996; Park et al., 1998). Systemically administered sRAGE caused dose-dependent suppression of tumor volume (FIG. 7G ), though the effect was less dramatic than with tumor mutants producing sRAGE (S1,2,3; Table 1), probably due to higher local concentrations of soluble receptor in sRAGE-transfected tumors. - As amphoterin and RAGE were both present in the tumor bed, a direct way to ascertain their mutual involvement in tumor progression was using monospecific polyclonal antibodies raised to each. Rabbit F(ab′)2 fragments prepared from the antibodies to RAGE and/or amphoterin were administered to immunocompromised (severe combined immunodeficiency, SCID) mice from the time of inoculation with C6 glioma cells.
- Compared with SCID mice receiving nonimmune F(ab′)2, animals treated anti-amphoterin or anti-RAGE F(ab′)2 demonstrated significant reduction in tumor volume after 21 days (4,935±410 vs 2,486±438 mm3 and 2,368±270 mm3, respectively) (
FIG. 7H ). Furthermore, simultaneous treatment of SCID mice with both anti-RAGE and anti-amphoterin F(ab′)2 resulted in greater reduction in tumor volume compared with animals receiving nonimmune F(ab′)2 (p<0.00001) or either antibody alone. These data substantiated a role for RAGE-amphoterin interaction in modulating tumor progression in a primary tumor model. - Blockade of RAGE suppresses distant metastasis. To ascertain whether RAGE might also contribute to distant tumor spread, the Lewis lung carcinoma model (O'Reilly et al., 1994), in which distant metastases flourish upon removal of primary tumor, was employed. Both RAGE and amphoterin were present in Lewis lung carcinoma cells (FIG. 7A1,
lane 2; and FIG. 7A2,lane 2, respectively), and could be localized to the cell surface by immunocytochemistry (not shown). To test our hypotheses, we first prepared stably-transfected Lewis lung carcinoma cells elaborating excess sRAGE. However, following implantation into C57BL/6J mice marked suppression of local tumor growth resulted (data not shown), thereby abrogating the usefulness of this model. As an alternative strategy to block interaction of ligands (amphoterin) with tumor cell RAGE, SRAGE was administered just prior to and after resection of primary tumor. Compared to treatment with vehicle alone, murine serum albumin (MSA), administration of sRAGE resulted in dose-dependent suppression of lung surface metastases (FIG. 8A ). Lung surface metastases, observed in vehicle (MSA)-treated mice (8.7±1.4;FIG. 8A , B, F), were virtually undetectable at an SRAGE dose of 100 μg/day (1.0±0.3 and p<0.0001;FIG. 8A , E, G). These findings suggested that blocking access to cell surface RAGE in the presence of excess sRAGE potently suppressed tumor metastatic capacity. - Blockade of RAGE and/or amphoterin suppresses invasion and migration of C6 glioma cells: in vitro analyses. It is essential to note that tumors produced by each of the C6 glioma cell transfectants (F, S, and T) demonstrated the same growth rate as tumors from mock-transfected control C6 cells (M), based on the slope of plots of the natural log of tumor volume versus time post-tumor cell inoculation (Table 2). Furthermore, tumor cell proliferation in vitro, comparing wild-type C6 glioma cells with each of the stable transfectants (M, F, T and S), was unchanged (not shown), and incubation of C6 glioma cells with sRAGE was without effect (
FIG. 9A ). Similarly, no differences were noted in the rate of tumor growth comparing MSA- and sRAGE-treated C6 gliomas, or tumors from animals receiving anti-RAGE or anti-amphoterin F(ab′)2 (Table 2). Thus, as tumor proliferative capacity was not affected, we focussed our attention on other mechanisms, especially RAGE-amphoterin-mediated modulation of tumor cell invasive and migratory properties. -
TABLE 2 Tumor proliferation rate did not differ among mice treated systemically with murine serum albumin (MSA), murine sRAGE or nonimmune/anti-RAGE/anti-amphoterin F(ab′)2 fragments. p value; compared Natural log tumor with treatment volume per day vs time; with MSA or Treatment mean ± standard error nonimmune F(ab′)2 MSA 0.27 ± 0.03 — sRAGE, 2 _g 0.31 ± 0.04 p > 0.1 sRAGE, 20 _g 0.30 ± 0.04 P > 0.1 nonimmune F(ab′)2 0.26 ± 0.02 — anti-RAGE F(ab′)2 0.31 ± 0.03 p > 0.1 anti-amphoterin F(ab′)2 0.29 ± 0.04 p > 0.1 anti-RAGE + 0.35 ± 0.05 p > 0.1 anti-amphoterin F(ab′)2 - In vitro tumor cell invasion assays were performed using the Matrigel model. Compared with mock-transfected C6 glioma cells, those bearing full-length RAGE demonstrated enhanced invasion (419±3 vs 550±7 cells; p<0.00001). In contrast, transfected C6 clones bearing the tail-deletion RAGE mutant or overexpressing sRAGE revealed diminished invasion of the Matrigel (265±4, p<0.00001 vs mock; and 282±7 cells, p<0.00001 vs mock, respectively) (
FIG. 9B ). Furthermore, C6 glioma cells incubated with sRAGE displayed dose-dependent suppression of tumor cell invasion compared with untreated controls; at the highest dose of SRAGE, 100 μg/ml, tumor cell invasive capacity was substantially decreased, 462±10 vs 147±8 cells; (p<0.00001;FIG. 9C ). Finally, treatment of tumor cells with anti-RAGE and/or anti-amphoterin IgG suppressed C6 cell invasion compared with nonimmune IgG-treated cells (FIG. 9D ) These findings suggested that RAGE was an important mediator of tumor cell invasive capacity. Disengagement of RAGE from either its ligand (amphoterin) in the presence of sRAGE, or from intracellular signalling mechanisms with the tail-deletion mutant, inhibited the ability of tumor cells to invade the gel of matrix proteins. - Since cellular migration is an important component of tumor cell invasiveness, the effect of blocking the amphoterin-RAGE axis was investigated in this system. Compared with mock-transfected C6 glioma, those clones expressing full-length RAGE exhibited increased-migration (216±3 vs 293±4 cells, respectively; p<0.00001) (
FIG. 9E ). In contrast, those expressing either tail-deletion RAGE or sRAGE exhibited diminished migration compared with mock-transfected clones (152±3 cells, p<0.00001 vs mock; and 142±3 cells, p<0.00001 vs mock; respectively) (FIG. 9E ). Similarly, incubation of C6 glioma cells with sRAGE suppressed migration in a dose-dependent manner. Compared with cells treated with MSA, those treated with the highest dose of sRAGE, 100 μg/ml, demonstrated a substantial reduction in migration (222±4 vs 106±3 cells, respectively; p<0.00001) (FIG. 9F ). Additional support for a role of amphoterin-RAGE interaction in mediating. C6 glioma migration ability was demonstrated by suppressed cell movement in the presence of anti-RAGE IgG, anti-amphoterin IgG or both antibodies, compared with those treated with nonimmune IgG (FIG. 9G ). - Several other mechanisms were considered through which amphoterin engagement of RAGE might suppress tumor growth in vivo, including attachment of tumor cells to the matrix, angiogenesis, and expression of cellular collagenolytic and plasmin activity. Blockade of RAGE in the presence of sRAGE did not affect tumor cell attachment to a Matrigel-coated substrate for up to 60 min after plating (
FIG. 10A ). At 30 mins after plating, C6 glioma cells treated with MSA, 200 μg/ml, revealed 56±4% attachment; and those treated with sRAGE, 100 μg/ml, revealed 50±3% attached; p=0.19 (FIG. 10A ). Similarly, angiogenesis, assessed in the mouse cornea assay was not adversely affected by administration of sRAGE. Basic FGF-induced angiogenesis elicited new capillary growth from the corneal limbus in C57BL/6J mice which was not different whether animals were treated with either MSA or sRAGE (3.1±0.3 vs 2.7±0.2 mm2 angiogenic area; p=0.23;FIG. 10B ). Furthermore, proliferation of cultured HUVEC was not significantly altered in the presence of sRAGE when compared with cells treated with MSA (data not shown). Primary differences in tissue-degradative capacity were also not evident in tumor cells treated with either MSA or sRAGE, as measured by activity of type IV collagenase (FIG. 10C ) or plasmin (FIG. 10D ). - Molecular mechanisms underlying tumorigenesis comprise a complex mesh of processes promoting unchecked cellular proliferation, invasion and induction of neovessel formation, as well as means of evading the immune response and buttressing metabolic adaptation to nutritional stress. Upregulation of both amphoterin and RAGE in tumor cells provides an autocrine means for modulating cellular properties in a sustained manner within the neoplasm. Previous studies showed that amphoterin engagement of RAGE on neuron-like cells induced neurite outgrowth and enhanced expression of the receptor via Sp1 sites within the promoter of the RAGE gene (Li et al., 1998; Li and Schmidt, 1997). Furthermore, amphoterin and RAGE have been colocalized to the leading edges of neurites (Parkkinen et al., 1993; Hori et al., 1995). These observations suggested the potential of RAGE-mediated modification of cellular properties to impart invasiveness, and implied that the impact of amphoterin-RAGE interaction might confer an ascending spiral of abnormal cellular behavior; increased expression of amphoterin causing, in turn, enhanced expression of the receptor, thereby further accentuating amphoterin-RAGE-induced changes in cellular properties. Signals regulating RAGE and amphoterin expression might thus contribute importantly to tumor cell phenotype. This situation may prove analogous to tumor expression of type IV collagenase activity (Liotta et al., 1980), Neural Cell Adhesion Molecule-1 (Michalides et al., 1994), CD44 (Ladeda et al., 1998), and certain matrix metalloproteinases (Murray et al., 1996), in which the degree of expression of these mediators has been shown to correlate with tumor invasive and metastatic capacity. The wide distribution of RAGE and amphoterin transcripts in human colon, lung, kidney and other tumors (not shown) suggests that their presence might also underlie basic elements of tumor cell behavior.
- Amphoterin binding to cell surface RAGE actively recruited signal transduction mechanisms to bring about RAGE-induced changes in cellular phenotype. Transfection of the tail deletion mutants of RAGE in C6 glioma cells, which endogenously expressed low levels of wild-type RAGE, conferred a dominant-negative modulation of cellular properties both in vivo, by attenuated growth of primary and metastatic tumors, and in vitro, by diminished migration and invasion. These observations suggested parallels to the biology of integrins, a family of cell surface transmembrane proteins that participate in tumor attachment, invasion and migration (Hynes, 1992). The intracellular domains of integrins are connected to cytoskeletal proteins and intracellular signal transduction pathways; these domains are postulated to mediate “inside-out” signalling, thereby modulating intercellular communication, cellular differentiation and phenotype (Ginsberg et al., 1992; Heino, 1996). Studies are in progress to delineate components of the molecular complex through which the cytosolic domain of RAGE engages signal transduction machinery and triggers effector mechanisms promoting cellular migratory and invasive properties.
- Amphoterin-RAGE modulation of tumor cell properties is distinct from that of other pathways directly regulating cellular proliferation, angiogenesis, tumor cell-matrix interaction or degradation of critical barrier substrates, such as fibronectin and collagen type IV. In contrast, amphoterin binding to RAGE neither increased the rate of tumor cell growth nor changed tumor cell apoptotic index or p53 expression (Hartwell and Kastan, 1994) (not shown). Blockade of RAGE was without effect on neovessel ingrowth, attachment of tumor cells to matrix elements or tumor cell digestion of basement membrane molecules. Thus, the amphoterin-RAGE axis appeared to exert effects distinct from other well-studied regulators of tumor cell division, neovessel formation, and cell-matrix interactions. These considerations emphasize the role of alternate mechanisms, such as interplay of integrins, laminin receptors, cadherins, cellular adhesion molecules, selectins and/or CD44 in mediating attachment and engagement of structural interfaces in the tumor bed (Price et al., 1997). However, these observations also highlight the possibility that blockade of RAGE may impact on properties of tumor cells in a manner quite distinct from those mentioned above, thereby marking it as a likely complementary target for therapy. Conversely, the effect of suppressing amphoterin-RAGE interaction within the tumor bed may augment the effects of other anti-tumor approaches by virtue of their impact on diverse cellular properties. Extrapolation of this concept to the clinical setting suggests that blockade of RAGE might enhance conventional chemotherapy and/or radiotherapy, or newer modalities limiting effective angiogenesis within the enlarging tumor (O'Reilly et al., 1994; Kakeji and Teicher, 1997; Mauceri et al., 1998).
- One striking feature of our data is the more effective suppression of tumor cell growth achieved through local expression of sRAGE or dominant-negative RAGE, compared with administration of anti-amphoterin IgG. Although this may reflect, in part, limited penetration of the immune IgG into the tumor bed, it might also suggest the existence of other ligands capable of stimulating RAGE within the tumor itself. In this context, S100/calgranulin proteins, well-known as tumor markers (Cochran et al., 1993; Davies et al., 1993), have been recently identified as RAGE ligands (Hofmann et al., 1998), and may provide another venue for activation of the receptor in the tumor milieu. Taken together, our findings strongly suggest that amphoterin engagement of RAGE modulates potent forces within the tumor and its microenvironment favoring successful local and distant invasion, thereby conferring a survival advantage to primary and metastatic tumors. In contrast, the lack of effect of RAGE blockade on angiogenesis, cellular proliferative rate or tissue-degradative properties assigns amphoterin-RAGE interaction a novel and, potentially, pathophysiologically important role in the modulation of tumor cell behavior.
- Cell lines. Rat glial cells (C6), murine Lewis lung carcinoma cells (LLC), and NIH/3T3 cells were purchased from the American Type Culture Corporation (ATCC; Rockville, Md.) and cultured according to standard ATCC protocols. Human umbilical vein endothelial cells (HUVEC) were isolated and characterized as previously described (Jaffe et al., 1973) and maintained in Endothelial Cell Growth Medium (EGM; Clonetics, Walkersville Md.) according to the manufacturer's instructions.
- Development of RAGE constructs. Human RAGE cDNA (Neeper et al., 1992) was inserted into the mammalian expression vector pcDNA3 (Invitrogen, Carlsbad Calif.) behind the human cytomegalovirus major intermediate early promoter/enhancer region by employing enzyme restriction sites Kpn1 and XhoI. Human cytosolic tail deletion RAGE cDNA was composed of a construct in which the entire cytosolic domain coding sequence was deleted (Neeper et al., 1992) and inserted into pcDNA3 vector by employing EcoRV and Xba1 enzyme restriction sites. Human soluble RAGE cDNA was composed of a construct in which both the transmembrane spanning domain and cytosolic domain coding sequences were deleted (Neeper et al., 1992) and inserted into pcDNA3 vector by employing EcoRV and Xba1 enzyme restriction sites. All constructs were first transiently-transfected into NIH 3T3 cells and evidence for expression was determined by immunoblotting employing monospecific, polyclonal anti-human RAGE IgG as previously characterized (Schmidt et al., 1992; Hori et al., 1995). This antibody was selectively prepared against soluble human RAGE, therefore, it recognizes the products of all three cDNA constructs.
- Development of stably-transfected RAGE tumor cells. C6 rat glioma cells were transfected by employing Lipofectamine (Life Technologies, Grand Island, N.Y.) according to the manufacturer's instructions. Cells were selected in the presence of geneticin (G418), 1.5 mg/ml (Life Technologies), and individual clones were isolated by means of limiting dilution (Pelicci et al., 1992). Selected clones were tested for RAGE expression by immunoblotting (Schmidt et al., 1992). Four transfected lines were produced as follows: (1) mock transfectants (M), transfected with vector alone but grown and maintained exactly as the RAGE transfectants; (2) full-length RAGE transfectants (F), transfected with construct encoding full-length human RAGE; (3) tail-deletion RAGE transfectants (T), transfected with construct encoding RAGE lacking the cytosolic domain; and (4) soluble RAGE transfectants (S); transfected with construct in which both the transmembrane spanning domain and cytosolic domains were deleted. In each case, three independent clones were established for each transfected cell line.
- Production of murine soluble RAGE. The construct encoding murine soluble RAGE was placed into the baculovirus expression system and soluble murine RAGE expressed in Spodoptera frugiperda 9 (Sf9) cells (Invitrogen). Murine sRAGE was purified from cellular supernatant as previously described (Park et al., 1998) and devoid of endotoxin prior to intraperitoneal administration to mice by chromatography onto Detox-igel columns (Pierce, Arlington Heights, Ill.). Absence of endotoxin was documented using a kit from Sigma (St. Louis, Mo.) (limulus amebocyte assay). Murine serum albumin was purchased from Sigma.
- Generation of anti-RAGE and anti-amphoterin F(ab′)2 fragments. Monospecific, polyclonal rabbit anti-human RAGE IgG was prepared and characterized as described. Recombinant rat amphoterin was prepared and characterized as described (Hori et al., 1995). This material was employed to immunize rabbits; serum was then obtained and IgG prepared (Pierce). Nonimmune rabbit serum was purchased from Pocono Rabbit Farms (Canadensis, Pa.). In all three cases, F(ab′)2 fragments of IgGs were prepared using a kit from Pierce and characterized as per the manufacturer's instructions.
- Immunoblotting. Immunoblotting of cultured tumor cells was performed by subjecting cells to sonication with a
Branson Ultrasonics 250 Sonicator (Branson Ultrasonics, Danbury Conn.) in buffer containing tris, 0.02M, pH 7.4; NaCl, 0.1 M; PMSF, 0.002M; leupeptin, 0.5 μg/ml; and pepstatin (0.7 μg/ml) in the presence of octyl-beta-D-glucopyranoside (1%; Fisher Scientific, Fairlawn, N.J.) at 4° C. followed by eight hrs gentle rotation. At the end of that time, cellular extracts were subjected to centrifugation, 11,000×g for 20 mins at 4° C. Supernatant was collected and protein concentration determined using an assay system from Bio-Rad (Hercules Calif.). Similarly, tumors excised from mice were placed in the same buffer as above, except tissue was subjected to homogenization (Brinkman, Old Westbury, N.Y.). In each case, 30 μg total protein was subjected to electrophoresis by SDS-PAGE (10% in the case of immunoblotting for detection of RAGE, and 15% in the case of immunoblotting for detection of amphoterin, Novex, San Diego, Calif.). After electrophoresis, components of the gels were transferred to nitrocellulose membranes (Novex) and subjected to immunoblotting employing rabbit anti-RAGE IgG (25 μg/ml) or rabbit anti-rat amphoterin IgG (25 μg/ml) as above. Binding of primary antibody was identified by employing horse radish peroxidase-conjugated goat anti-rabbit IgG (Sigma). In the case of tumor tissue, immunoblotting was performed using anti-p53 IgG (M-19) (Santa Cruz Biotechnology). Binding of primary antibody was identified by employing horse radish peroxidase-conjugated rabbit anti-goat IgG (Sigma). In all cases, binding of secondary antibody was detected using ECL, chemiluminescence kit from Amersham Pharmacia Biotech (Piscataway, N.J.) according to the manufacturer's instructions. For sRAGE-generating clones, transfected tumor cells were plated onto tissue culture-treated plastic dishes containing 6 wells for 12 hrs in complete medium. At the end of that time, cells were washed and then incubated in medium without FBS for 24 hrs. Supernatant was then collected and subjected to SDS PAGE/immunoblotting as above. Densitometric analysis of band intensity was performed using Image Quant (Molecular Dynamics, Foster City, Calif.). - Assessment of apoptosis in C6 glioma tumor. At time of sacrifice, C6 glioma tumors were removed from nude mice and fixed in formalin (10%). Paraffin-embedded tissue sections were prepared, each 5 μm thick. Assessment of apoptosis was made by TUNEL assay employing the In Situ Cell Death Detection kit (Boehringer Mannheim, Indianapolis, Ind.) according to the manufacturer's instructions.
- Model of local tumor growth: effect of soluble RAGE or RAGE-transfection. Rat C6 glioma cells (wild-type or cloned transfectants as above), 1×10 5/0.1 ml PBS, were injected subcutaneously into the dorsal midline of female NCR immunocompromised (nude) mice, age 4-6 weeks (Taconic Farms, ùGermantown, N.Y.). Where indicated, immediately after injection of tumor cells, mice received daily intraperitoneal injections of protein vehicle murine serum albumin (MSA), or the indicated concentration of murine sRAGE. Tumors were measured on
days - Model of local tumor growth: effect of blockade of amphoterin and/or RAGE. Wild-type rat C6 glioma cells were injected into the dorsal midline of female mice with severe combined immunodeficiency (SCID; Taconic Farms). The mice were divided into four groups, each receiving intraperitoneal injection of the indicated F(ab′)2 fragment every three days: the first received nonimmune rabbit F(ab′)2 fragments (400 μg/dose); the second received rabbit anti-RAGE F(ab′)2 fragments (200 μg/dose); the third received rabbit anti-amphoterin F(ab′)2 fragments (200 μg/dose); and the fourth group received rabbit anti-RAGE F(ab′)2 fragments (200 μg/dose)+anti-amphoterin F(ab′)2 fragments (200 μg/dose). Tumors were measured and all mice sacrificed on
day 21. - Model of metastatic tumor growth and invasion. A model of tumor metastasis was established according to previously-published procedures (O'Reilly et al., 1994). Cultured Lewis lung murine carcinoma cells (2×106 in 0.1 ml PBS) were injected into the dorsal midline of male, 6-8 week old C57BL/6J mice (Jackson Laboratories, Bar Harbor, Me.). Primary tumors were surgically excised when tumor volume reached 1,500 mm3 (usually on day 14). Three days prior to removal of primary tumor, mice received the indicated dose of sRAGE or MSA once daily by intraperitoneal injection. Treatment was continued until sacrifice, 21 days after removal of primary tumor. At sacrifice, numbers of lung surface metastases were counted under 4×-magnification using an Olympus microscope (Melville N.Y.) upon intratracheal injection of India Ink (15%).
- Murine corneal angiogenesis assay. To determine if administration of murine soluble RAGE altered angiogenesis, a corneal micropocket angiogenesis assay was performed as described (O'Reilly et al., 1994). Briefly, pellets containing basic fibroblast growth factor (bFGF; Intergen, Purchase N.Y.) and sucralfate (Bukh Meditec, Denmark) were introduced into corneal pockets of male, 6-8 week old C57BL/6J mice. Mice received either intraperitoneal injection of murine serum albumin or murine soluble RAGE.
- Mice were sacrificed after S days treatment, and the eyes were examined under slit-lamp biomicroscopy (Nikon FS-2, Melville N.Y.) for angiogenic response. Area of angiogenic response was calculated by employing the formula for an ellipse: A=[(CH×0.4)×VL (mm)×1]/2, where CH=clock hours with a 360° reticule (300 equals one clock hour) and VL=maximal vessel length.
- Cell proliferation assay. Proliferation of cultured HUVEC or C6 glioma cells was performed on 96-well tissue culture-treated wells (Corning, Corning N.Y.). Initial cell density at plating was 1×103 cells/well. Cells were incubated for 3 hours in standard medium to allow attachment. At the end of that time, the indicated concentrations of either MSA or sRAGE were added; medium was changed daily and fresh sRAGE or MSA added. Three days after plating, cell number was assessed using the CyQUANT Cell Proliferation Assay kit (Molecular Probes, Eugene, Oreg.) according to the manufacturer's instructions. Absence of untoward cell death was documented in both conditions by exclusion of trypan blue (Sigma).
- In vitro migration and invasion assays. Assessment of in vitro tumor cell migration was performed as previously described (Valente et al., 1998). Briefly, wild-type tumor cells as indicated (3×106) were added to the upper chambers of Transwell 6-well plates (Costar, Cambridge Mass.), 8 um pore-sized filter. The chemoattractant, conditioned medium from NIH 3T3 cells, was added to the lower chamber. Cells were incubated with the indicated concentrations of either MSA or sRAGE for 5 hrs at 37° C. in an incubator containing CO2 (5%). In other experiments, tumor cells were pretreated with the indicated concentration of nonimmune IgG, anti-RAGE IgG, anti-amphoterin IgG or anti-RAGE+anti-amphoterin IgG for one hr at 4° C. prior to placement in the Transwell chambers. In both cases, after 5 hrs, cells remaining on the upper side of the filter were gently-removed by cotton swabbing. The bottom side of the filter was then fixed in methanol and stained with Giemsa (Sigma). Cells in 10 hpf were then counted. Migration assays on each of the four groups of transfected clones was performed similarly. Invasion assays were performed in an identical manner except that the upper chambers of the Transwell culture dishes were pretreated with Matrigel, 500 μg/filter (Becton Dickinson, Bedford Mass.) as previously described (Albini et al., 1987).
- In vitro attachment assays. 96-well tissue culture treated-dishes (Corning) were coated with Matrigel (30 μg/well). To each well were then added rat C6 glioma cells (1×104 cells per well) in the presence of SRAGE or MSA. At the indicated times, wells were depleted of medium by aspiration and washed twice with PBS (Life Technologies). At those time points, cell number per well was quantified using the CyQUANT assay kit.
- Assessment of type IV collagenase activity. Assessment of activity of type Iv collagenase was performed as previously described (Nakajima et al., 1987). Briefly, N-[propionate-2,3-3H]-propionylated human type IV collagen (NEN Life Science, Boston Mass.) was admixed with unlabelled human type IV collagen (Life Technologies) and adjusted to 100,000 cpm/200 μg/ml in acetic acid (0.5M). Aliquots containing 3,000 cpm of the type IV collagen were placed into the wells of 96 well tissue culture-treated dishes and dried overnight in a laminar air flow hood. Rat C6 glioma cells (2×105 in 0.2 ml medium) were placed onto the dried 3H-collagen film and incubated at 37° C. in a humidified atmosphere (CO2, 5%). Cells were treated with either MSA (200 μg/ml) or sRAGE (100 μg/ml). At 1, 3, 6, 12 or 24 hrs, the culture supernatant was removed and mixed with solution containing ice-cold trichloroacetic acid (10%) and tannic acid (0.5%) (0.05 ml). After 30 mins incubation at 4° C., the mixture was subjected to centrifugation at 10,000×g for 10 mins at 4° C. to precipitate undigested material. The radioactivity of the supernatant was measured in a liquid scintillation counter (LKB, Gaithersburg, Md.).
- Assessment of plasmin activity. Rat C6 glioma cells (2×105 cells/0.2 ml phenol-free medium) were placed into 96 well tissue culture-treated dishes. Cells were incubated in the presence of MSA (200 μg/ml) or sRAGE (100 μg/ml) in medium containing Spectrozyme PL (0.5M, American Diagnostica, Greenwich Conn.). At 1, 3, 6, 12 or 24 hrs, the plates were placed into a Bio Kinetics Reader (Bio Tek Instruments, Winooski Vt.) and A405nm recorded.
- Analysis of RAGE and amphoterin expression in human tumors. RNA derived from human tumors was generously provided by Dr. Benjamin Tycko, Columbia University Tumor Bank, Department of Pathology. Five micrograms of RNA were reverse transcribed with Superscript II (Life Technologies), according to the manufacturer's protocol. The following primers were employed for detection of transcripts for RAGE (5′-ACACTGCAGTCGGAGCTAAT-3′ (Seq. ID No. 7) and 5′-AAGATGACCCCAATGAGCAG-3′ (Seq. ID No. 8)) and for detection of amphoterin (5′-AAGAAGTGCTCAGAGAGGTG-31 (Seq. ID No. 9) and 5′-TAAGGCTGCTTGTCATCTGC-3′ (Seq. ID No. 10)). Conditions for PCR consisted of 40 amplification cycles employing 62° C. as the annealing temperature.
- Statistical analysis. Statistical comparisons among groups was determined using one-way analysis of variance (ANOVA); where indicated, individual comparisons were performed using students' t-test. Statistical analyses comparing the slopes of tumor growth rate curves were performed using a program in Microsoft Excel (Redmond Wash.). Statistical significance was ascribed to the data when p<0.05.
-
- Albini, A., Iwamoto, Y., Kleinman, H. K., Martin, G. R., Aaronson, S. A., Kozlowski, J. M., and McEwan, R. N. (1987) A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 47, 3239-3245.
- Benda, P., Lightbody, J., Sato, G., Levine, L., and Sweet, W. (1968) Differentiated rat glial cell strain in tissue culture. Science 161, 370-371.
- Brownlee, M., Cerami, A., and Vlassara, H. (1988) Advanced glycosylation endproducts in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318, 1315-1320.
- Cochran, A. J., Lu, H. F., Li, P. X., Saxton, R., and Wen, D. R. (1993) S-100 protein remains a practical marker for melanocytic and other tumors. Melanoma Res. 3, 325-330.
- Davies, B. R., Davies, M. P., Gibbs, F. E., Barraclough, R., and Rudland, P. S. (1993) Induction of the metastatic phenotype by transfection of a benign rat mammary epithelial cell line with the gene for p9Ka, a rat calcium-binding protein, but not with the oncogene EJ-ras-1.
Oncogene 8, 999-1008. - Fu, C., Pischetsrieder, M., Hofmann, M., Yan, S. F., Stern, D., Schmidt, A. M. (1998).
- Carboxymethyl-lysine AGE modifications of proteins are ligands for RAGE that activate cell signalling pathways. Circ. Suppl. 98, #1651.
- Ginsberg, M. H., Du, X., and Plow, E. F. (1992) Inside-out integrin signalling. Curr. Opin. Cell. Biol. 4, 766-771.
- Hartwell, L. H., and Kastan, M. B. (1994) Cell cycle control and cancer. Science 266, 1821-1828.
- Heino, J. (1996) Biology of tumor cell invasion: interplay of cell adhesion and matrix degradation. Int. J. Cancer 65, 717-722.
- Hofmann, M., Drury, S., Fu, C., Li, J., Qu, X., Qu, W., and Schmidt, A. M. (1998) EN-RAGE (Extracellular Novel RAGE binding protein) activates endothelial cells and macrophages to mediate inflammatory responses. Circ. (Suppl). 98, #1657.
- Hori, O., Brett, J., Slattery, T., Cao, R., Zhang, J., Chen, J., Nagashima, M., Nitecki, D., Morser, J., Stern, D., and Schmidt, A. M. (1995). The receptor for advanced glycation endproducts (RAGE) is a cellular binding site for amphoterin: mediation of neurite outgrowth and coexpression of RAGE and amphoterin in the developing nervous system. J. Biol. Chem. 270, 25752-25761.
- Hynes, R. O. (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69, 11-25.
- Jaffe, E., Nachman, R., Becker, C., and Minick, R. (1973) Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 52, 2745-2756.
- Kakeji, Y., and Teicher, B. A. (1997) Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest.
New Drugs 15, 39-48. - Ladeda, V., Aguirre Ghiso, J. A., and de Kier JCffe, E. B. (1998) Function and expression of CD44 during spreading, migration and invasion of murine carcinoma cells. Exp. Cell Res. 242, 515-527.
- Lander, H. L., Tauras, J. M., Ogiste, J. S., Moss, R. A., and A. M. Schmidt. (1997) Activation of the Receptor for Advanced Glycation Endproducts triggers a MAP Kinase pathway regulated by oxidant stress. J. Biol. Chem. 272, 17810-17814.
- Li, J., Qu, X., and A. M. Schmidt. (1998) Spi binding elements in the promoter of RAGE are essential for amphoterin-mediated gene expression in cultured neuroblastoma cells. J. Biol. Chemistry 273, 30870-30878.
- Li, J., and Schmidt, A. M. (1997). Characterization and functional analysis of the promotor of RAGE, the receptor for advanced glycation endproducts. J. Biol. Chem. 271, 16498-16506.
- Liotta, L. A., Tryggvason, K., Garbisa, S., Hart, I., Foltz, C. M., Shafie, S. (1980) Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284, 67-68.
- Mauceri, H. J., Hanna, N. N., Beckett, M. A., Gorski, D. H., Staba, M.-J., Stellato, K. A., Bigelow, K., Heimann, R., Gately, S., Dhanabal, M., Soff, G. A., Sukhatme, V. P., Kufe, D. W., and Weichselbaum, R. R. (1998) Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature 394, 2887-291.
- Michalides, R., Kwa, B., Springall, D., Van Zandwijk, N., Koopman, J., Hilkens, J., and Mooi, W. (1994) NCAM and lung cancer.
Int. J. Cancer 8, 34-37. - Murray, G. I., Duncan, M. E., O'Neil, P., Melvin, W. T., and Fothergill, J. E. (1996) Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat. Med. 2, 461-462.
- Nakajima, M., Welch, D. R., Belloni, P. N., and Nocolson, G. L. (1987) Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res. 47, 4869-4876.
- Neeper, M., Schmidt, A. M., Brett, J., Yan, S. D., Wang, F., Pan, Y. C., Elliston, K., Stern, D., and Shaw, A. (1992). Cloning and expression of RAGE: a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267, 14998-15004.
- O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328.
- Park, L., Raman, K. G., Lee, K. J., Lu, Y., Ferran, L. J., Chow, W. S., Stern, D., and Schmidt, A. M. (1998) Suppression of accelerated diabetic atherosclerosis by soluble Receptor for AGE (sRAGE).
Nature Medicine 4, 1025-1031. - Parkkinen, J., Raulo, E., Merenmies, J., Nolo, R., Kagander, E. O., Baumann, M., and Rauvala, H. (1993) Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. J. Biol. Chem. 268, 19726-19738.
- Parkkinen, J. and Rauvala, H. (1991) Interactions of plasminogen and tissue plasminogen activator (t-PA) with amphoterin. J. Biol. Chem. 266, 16730-16735.
- Pelicci, G., Lanfrancone, L., Grignani, F., McGlade, J., Cavallo, F., Formi, G., Nicoletti, I., Grignani, F., Pawson, T., and Pelicci, P. G. (1992) A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 70, 93-104.
- Price, J. T., Bonovich, M. T., and Kohn, E. C. (1997) The biochemistry of cancer dissemination. Critical Rev. in Biochem. and Molecular Biol. 32, 175-253.
- Rauvala, H., Merenmies, J., Pihlaskari, R., Korkolainen, M., Huhtala, M.-L., and Panula, P. (1988) The adhesive and neurite-promoting molecule p30: analysis of the amino-terminal sequence and production of antipeptide antibodies that detect p30 at the surface of neuroblastoma cells and of brain neurons. J. Cell. Biol. 107, 2293-22305.
- Rauvala, H., and Pihlaskari, R. (1987) Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. J. Biol. Chem. 262, 16625-16635.
- Schafer, B. W., and Heinzmann, C. W. (1996). The S100 family of EF-hand calcium-binding proteins: functions and pathology.
TIBS 21, 134-140. - Schmidt, A. M., Vianna, M., Gerlach, M., Brett, J., Ryan, J., Kao, J., Esposito, C., Hegarty, H., Hurley, W., Clauss, M., Wang, F., Pan, Y. C., Tsang, T. C., and Stern, D. (1992) Isolation and characterization of binding proteins for advanced glycosylation endproducts from lung tissue which are present on the endothelial cell surface. J. Biol. Chem. 267, 14987-14997.
- Sell, D., and Monnier, V. (1989) Structure elucidation of a senescence cross-link from human extracellular matrix; implication of pentoses in the aging process. J. Biol. Chem. 264, 21597-21602.
- Selkoe, D. (1994) Alzheimer's disease: a central role for amyloid. J. Neuropathol. Exp. Neurol 53, 438-447.
- Sisodia, S., and Price, D. (1995) Role of the beta-amyloid protein in Alzheimer's disease. FASEB J. 9, 366-370.
- Valente, P., Fassina, G., Melchior, A., Masiello, L., Cilli, M., Vacca, A., Onisto, M., Santi, L., Stetler-Stevenson, W. G., and Albini, A. (1998) TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int. J. Cancer 75, 246-253.
- Wautier, J-L., Zoukourian, C., Chappey, O., Wautier, M. P., Guillausseau, P. J., Cao, R., Hori, O., Stern, D., and Schmidt, A. M. (1996) Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: soluble receptor for advanced glycation endproducts blocks hyperpermeability. J. Clin. Invest. 97, 238-243.
- Weast, R. (1966) Handbook of Chemistry and Physics. The Chemical Rubber Company, Cleveland, Ohio.
- Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Nagashima, M., Morser, J., Migheli, A., Nawroth, P., Godman, G., Stern, D., and Schmidt, A. M. (1996). RAGE and amyloid beta peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-691.
- Yan, S-D., Schmidt A-M., Anderson, G., Zhang, J., Brett, J., Zou, Y-S., Pinsky, D., and Stern, D. (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation endproducts with their receptors/binding proteins. J. Biol. Chem. 269, 9889-9897.
- Yan, S. D., Zhu, H., Fu, J., Yan, S. F., Roher, A., Tourtellotte, W., Rajavashisth, T., Chen, X., Stern, D., and Schmidt A. M. (1997). Amyloid-beta peptide-RAGE interaction elicits neuronal expression of M-CSF: a proinflammatory pathway in Alzheimer's disease. Proc. Natl. Acad. Sci. 94, 5296-5301.
- Zimmer, D. B., Cornwall, E. H., Landar, A., and Song, W. (1995). The S100 protein family: history, function, and expression. Brain Research Bulletin 37, 417-429.
Claims (33)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/891,680 US20090191210A1 (en) | 1998-04-17 | 2007-08-09 | Method for inhibiting tumor invasion or spreading in a subject |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/062,365 US6465422B1 (en) | 1998-04-17 | 1998-04-17 | Method for inhibiting tumor invasion or spreading in a subject |
PCT/US1999/008427 WO1999054485A1 (en) | 1998-04-17 | 1999-04-16 | A method for inhibiting tumor invasion or spreading in a subject |
US68946900A | 2000-10-12 | 2000-10-12 | |
US11/891,680 US20090191210A1 (en) | 1998-04-17 | 2007-08-09 | Method for inhibiting tumor invasion or spreading in a subject |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US68946900A Continuation | 1998-04-17 | 2000-10-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090191210A1 true US20090191210A1 (en) | 2009-07-30 |
Family
ID=22042008
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/062,365 Expired - Fee Related US6465422B1 (en) | 1998-04-17 | 1998-04-17 | Method for inhibiting tumor invasion or spreading in a subject |
US09/851,071 Expired - Fee Related US7125675B2 (en) | 1998-04-17 | 2001-05-08 | Method for inhibiting tumor invasion or spreading in a subject |
US11/891,680 Abandoned US20090191210A1 (en) | 1998-04-17 | 2007-08-09 | Method for inhibiting tumor invasion or spreading in a subject |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/062,365 Expired - Fee Related US6465422B1 (en) | 1998-04-17 | 1998-04-17 | Method for inhibiting tumor invasion or spreading in a subject |
US09/851,071 Expired - Fee Related US7125675B2 (en) | 1998-04-17 | 2001-05-08 | Method for inhibiting tumor invasion or spreading in a subject |
Country Status (6)
Country | Link |
---|---|
US (3) | US6465422B1 (en) |
EP (1) | EP1071794A4 (en) |
JP (1) | JP2002512038A (en) |
AU (1) | AU3495799A (en) |
CA (1) | CA2325573A1 (en) |
WO (1) | WO1999054485A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050129682A1 (en) * | 2003-05-09 | 2005-06-16 | Schmidt Ann M. | RAGE G82S-related methods and compositions for treating inflammatory disorders |
US20060078562A1 (en) * | 2004-08-03 | 2006-04-13 | Mjalli Adnan M | RAGE fusion proteins and methods of use |
US20080214453A1 (en) * | 1996-11-22 | 2008-09-04 | The Trustees Of Columbia University In The City Of New York | Methods for treating inflammation |
US20090220484A1 (en) * | 2005-03-17 | 2009-09-03 | Ann Marie Schmidt | Rage/Diaphanous Interaction and Related Compositions and Methods |
US20090228997A1 (en) * | 1998-10-06 | 2009-09-10 | Ann Marie Schmidt | Extracellular novel RAGE binding protein ( EN-RAGE) and uses thereof |
US20100255081A1 (en) * | 1996-11-22 | 2010-10-07 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
US20100254983A1 (en) * | 2007-06-07 | 2010-10-07 | Ann Marie Schmidt | Uses of rage antagonists for treating obesity and related diseases |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6465422B1 (en) * | 1998-04-17 | 2002-10-15 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting tumor invasion or spreading in a subject |
US6613801B2 (en) | 2000-05-30 | 2003-09-02 | Transtech Pharma, Inc. | Method for the synthesis of compounds of formula I and their uses thereof |
US6908741B1 (en) | 2000-05-30 | 2005-06-21 | Transtech Pharma, Inc. | Methods to identify compounds that modulate RAGE |
WO2002030889A2 (en) | 2000-10-13 | 2002-04-18 | The Trustees Of Columbia University In The City Of New York | A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury |
WO2002070473A2 (en) | 2001-03-05 | 2002-09-12 | Transtech Pharma, Inc. | Carboxamide derivatives as therapeutic agents |
AU2002245590B2 (en) | 2001-03-05 | 2006-06-29 | Transtech Pharma, Inc. | Benzimidazole derivatives as therapeutic agents |
WO2003075921A2 (en) | 2002-03-05 | 2003-09-18 | Transtech Pharma, Inc. | Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage |
JP2006512900A (en) * | 2002-08-16 | 2006-04-20 | ワイス | Compositions and methods for the treatment of RAGE related diseases |
EP1771565B1 (en) * | 2004-07-20 | 2012-09-05 | The Feinstein Institute for Medical Research | Rage protein derivatives |
NZ552128A (en) | 2004-08-03 | 2009-09-25 | Transtech Pharma Inc | Rage fusion proteins without Fc hinge region and methods of use |
JP2008537874A (en) * | 2004-09-27 | 2008-10-02 | セントカー・インコーポレーテツド | sRAGE mimetibody, compositions, methods and uses |
WO2006077101A2 (en) * | 2005-01-18 | 2006-07-27 | Abbott Gmbh & Co. Kg | Ager-peptides and use thereof |
DE102005002353A1 (en) * | 2005-01-18 | 2006-07-27 | Abbott Gmbh & Co. Kg | Use of receptor multimerization epitope (RME) of advanced glycation end product receptor (AGER) as immunogen, useful for preparing antibodies for diagnosis and treatment of e.g. spinal injuries or diabetic complications |
US9291621B2 (en) | 2005-01-18 | 2016-03-22 | AbbVie Deutschland GmbH & Co. KG | AGER-peptides and use thereof |
WO2006119510A2 (en) * | 2005-05-04 | 2006-11-09 | Receptor Biologix, Inc. | Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same |
JP4779115B2 (en) * | 2005-12-16 | 2011-09-28 | 国立大学法人東北大学 | Postoperative prognostic method for early lung cancer |
AU2006327353B2 (en) * | 2005-12-23 | 2011-11-24 | Gcoder Systems Ab | Positioning pattern |
BRPI0707640A2 (en) * | 2006-02-09 | 2011-05-10 | Transtech Pharma Inc | rage fusion proteins and methods of use |
NZ571692A (en) | 2006-05-05 | 2012-01-12 | Transtech Pharma Inc | Rage fusion proteins, formulations, and methods of use thereof |
US20080199467A1 (en) * | 2007-02-15 | 2008-08-21 | Mjalli Adnan M M | Immunoglobulin fusion proteins and methods of making |
AU2008265983B2 (en) | 2007-06-14 | 2013-06-20 | Galactica Pharmaceuticals, Inc. | RAGE fusion proteins |
AU2010240569A1 (en) | 2009-04-20 | 2011-10-20 | Pfizer Inc. | Control of protein glycosylation and compositions and methods relating thereto |
TWI517850B (en) | 2009-09-30 | 2016-01-21 | Vtv治療有限責任公司 | Substituted imidazole derivatives and methods of use thereof |
CA2788355C (en) | 2010-02-18 | 2018-03-06 | Devi Reddy Gohimukkula | Phenyl-heteroaryl derivatives and methods of use thereof |
US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
WO2012170742A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Treatment and prevention of cancer with hmgb1 antagonists |
US9717710B2 (en) | 2012-10-05 | 2017-08-01 | Vtv Therapeutics Llc | Treatment of mild and moderate Alzheimer's disease |
Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5585344A (en) * | 1984-03-19 | 1996-12-17 | The Rockefeller University | Liver-derived receptors for advanced glycosylation endproducts and uses thereof |
US5767071A (en) * | 1995-06-07 | 1998-06-16 | Ixsys Incorporated | Sevenmer cyclic peptide inhibitors of diseases involving αv β3 |
US5864018A (en) * | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
US5981478A (en) * | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
US6465422B1 (en) * | 1998-04-17 | 2002-10-15 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting tumor invasion or spreading in a subject |
US6555651B2 (en) * | 1997-10-09 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Ligand binding site of rage and uses thereof |
US6555340B1 (en) * | 1998-10-06 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Nucleic acid encoding bovine extracellular rage binding protein (en-rage) |
US6563015B1 (en) * | 2000-08-14 | 2003-05-13 | The Trustees Of Columbia University In The City Of New York | Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof |
US6677299B2 (en) * | 2000-08-14 | 2004-01-13 | The Trustee Of Columbia University In The City Of New York | Method to increase cerebral blood flow in amyloid angiopathy |
US6753150B2 (en) * | 1998-10-05 | 2004-06-22 | The Trustees Of Columbia University In The City Of New York | Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
US20040121372A1 (en) * | 1998-10-06 | 2004-06-24 | The Trustees Of Columbia University In The City Of New York | Extracellular novel RAGE binding protein (EN-RAGE) and uses thereof |
US6790443B2 (en) * | 1996-11-22 | 2004-09-14 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
US20050129682A1 (en) * | 2003-05-09 | 2005-06-16 | Schmidt Ann M. | RAGE G82S-related methods and compositions for treating inflammatory disorders |
US20050170382A1 (en) * | 1999-10-06 | 2005-08-04 | The Trustees Of Columbia University In The City Of New York. | RAGE-related compositions |
US20060030527A1 (en) * | 2004-08-03 | 2006-02-09 | Mjalli Adnan M | Rage fusion proteins and methods of use |
US20060078562A1 (en) * | 2004-08-03 | 2006-04-13 | Mjalli Adnan M | RAGE fusion proteins and methods of use |
US7101838B2 (en) * | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
US20070014791A1 (en) * | 2003-09-05 | 2007-01-18 | Schmidt Ann M | Rage-related methods and copositions for treating glomerular injury |
US20070167360A1 (en) * | 2003-10-31 | 2007-07-19 | Yan Shi D | Methods for treating multiple sclerosis |
US7258857B2 (en) * | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
US20080019986A1 (en) * | 1999-08-13 | 2008-01-24 | The Trustees Of Columbia University In The City Of New York | Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof |
US20080171701A1 (en) * | 2000-10-13 | 2008-07-17 | The Cleveland Clinic Foundation | Method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury |
US20080207499A1 (en) * | 2005-06-29 | 2008-08-28 | Gaetano Barile | Rage-related methods for treating and preventing diabetic retinopathy |
US20080260717A1 (en) * | 2003-10-31 | 2008-10-23 | Trustees Of Columbia University In The City Of New York | Methods for Reducing Seizure-Induced Neuronal Damage |
-
1998
- 1998-04-17 US US09/062,365 patent/US6465422B1/en not_active Expired - Fee Related
-
1999
- 1999-04-16 AU AU34957/99A patent/AU3495799A/en not_active Abandoned
- 1999-04-16 JP JP2000544814A patent/JP2002512038A/en active Pending
- 1999-04-16 WO PCT/US1999/008427 patent/WO1999054485A1/en active Application Filing
- 1999-04-16 CA CA002325573A patent/CA2325573A1/en not_active Abandoned
- 1999-04-16 EP EP99916699A patent/EP1071794A4/en not_active Ceased
-
2001
- 2001-05-08 US US09/851,071 patent/US7125675B2/en not_active Expired - Fee Related
-
2007
- 2007-08-09 US US11/891,680 patent/US20090191210A1/en not_active Abandoned
Patent Citations (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5585344A (en) * | 1984-03-19 | 1996-12-17 | The Rockefeller University | Liver-derived receptors for advanced glycosylation endproducts and uses thereof |
US5981478A (en) * | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
US5767071A (en) * | 1995-06-07 | 1998-06-16 | Ixsys Incorporated | Sevenmer cyclic peptide inhibitors of diseases involving αv β3 |
US5864018A (en) * | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
US6790443B2 (en) * | 1996-11-22 | 2004-09-14 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
US20080214453A1 (en) * | 1996-11-22 | 2008-09-04 | The Trustees Of Columbia University In The City Of New York | Methods for treating inflammation |
US7700085B2 (en) * | 1996-11-22 | 2010-04-20 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
US7258857B2 (en) * | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
US7494972B2 (en) * | 1997-08-05 | 2009-02-24 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting accelerated atherosclerosis in a subject suffering from hypercholesterolemia or hypertriglyceridemia |
US7101838B2 (en) * | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
US6555651B2 (en) * | 1997-10-09 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Ligand binding site of rage and uses thereof |
US7125675B2 (en) * | 1998-04-17 | 2006-10-24 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting tumor invasion or spreading in a subject |
US6465422B1 (en) * | 1998-04-17 | 2002-10-15 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting tumor invasion or spreading in a subject |
US20040142391A1 (en) * | 1998-10-05 | 2004-07-22 | The Trustees Of Columbia University In The City Of New York | Methods for determining whether a compound is capable of inhibiting the interaction of a peptide with RAGE |
US6753150B2 (en) * | 1998-10-05 | 2004-06-22 | The Trustees Of Columbia University In The City Of New York | Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
US20040121372A1 (en) * | 1998-10-06 | 2004-06-24 | The Trustees Of Columbia University In The City Of New York | Extracellular novel RAGE binding protein (EN-RAGE) and uses thereof |
US7026444B2 (en) * | 1998-10-06 | 2006-04-11 | The Trustees Of Columbia University In The City Of New York | Extracellular novel RAGE binding protein (EN-RAGE) and uses thereof |
US7081241B1 (en) * | 1998-10-06 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Extracellular rage binding protein (EN-RAGE) and uses thereof |
US20090228997A1 (en) * | 1998-10-06 | 2009-09-10 | Ann Marie Schmidt | Extracellular novel RAGE binding protein ( EN-RAGE) and uses thereof |
US6555340B1 (en) * | 1998-10-06 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Nucleic acid encoding bovine extracellular rage binding protein (en-rage) |
US20080019986A1 (en) * | 1999-08-13 | 2008-01-24 | The Trustees Of Columbia University In The City Of New York | Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof |
US20050170382A1 (en) * | 1999-10-06 | 2005-08-04 | The Trustees Of Columbia University In The City Of New York. | RAGE-related compositions |
US6677299B2 (en) * | 2000-08-14 | 2004-01-13 | The Trustee Of Columbia University In The City Of New York | Method to increase cerebral blood flow in amyloid angiopathy |
US6825164B1 (en) * | 2000-08-14 | 2004-11-30 | The Trustees Of Columbia University In The City Of New York | Method to increase cerebral blood flow in amyloid angiopathy |
US6563015B1 (en) * | 2000-08-14 | 2003-05-13 | The Trustees Of Columbia University In The City Of New York | Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof |
US20080171701A1 (en) * | 2000-10-13 | 2008-07-17 | The Cleveland Clinic Foundation | Method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury |
US20050129682A1 (en) * | 2003-05-09 | 2005-06-16 | Schmidt Ann M. | RAGE G82S-related methods and compositions for treating inflammatory disorders |
US20070014791A1 (en) * | 2003-09-05 | 2007-01-18 | Schmidt Ann M | Rage-related methods and copositions for treating glomerular injury |
US20070167360A1 (en) * | 2003-10-31 | 2007-07-19 | Yan Shi D | Methods for treating multiple sclerosis |
US20080260717A1 (en) * | 2003-10-31 | 2008-10-23 | Trustees Of Columbia University In The City Of New York | Methods for Reducing Seizure-Induced Neuronal Damage |
US20060078562A1 (en) * | 2004-08-03 | 2006-04-13 | Mjalli Adnan M | RAGE fusion proteins and methods of use |
US20080075733A1 (en) * | 2004-08-03 | 2008-03-27 | Transtech Pharma, Inc. | Rage Fusion Proteins And Method Of Use |
US20060030527A1 (en) * | 2004-08-03 | 2006-02-09 | Mjalli Adnan M | Rage fusion proteins and methods of use |
US20090060925A1 (en) * | 2004-08-03 | 2009-03-05 | The Trustees Of Columbia University In The City Of | Rage Fusion Proteins and Methods of Use |
US20080207499A1 (en) * | 2005-06-29 | 2008-08-28 | Gaetano Barile | Rage-related methods for treating and preventing diabetic retinopathy |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080214453A1 (en) * | 1996-11-22 | 2008-09-04 | The Trustees Of Columbia University In The City Of New York | Methods for treating inflammation |
US20100255081A1 (en) * | 1996-11-22 | 2010-10-07 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
US20090228997A1 (en) * | 1998-10-06 | 2009-09-10 | Ann Marie Schmidt | Extracellular novel RAGE binding protein ( EN-RAGE) and uses thereof |
US20050129682A1 (en) * | 2003-05-09 | 2005-06-16 | Schmidt Ann M. | RAGE G82S-related methods and compositions for treating inflammatory disorders |
US8067371B2 (en) | 2003-05-09 | 2011-11-29 | The Trustees Of Columbia University In The City Of New York | RAGE G82S-related methods and compositions for treating inflammatory disorders |
US20060078562A1 (en) * | 2004-08-03 | 2006-04-13 | Mjalli Adnan M | RAGE fusion proteins and methods of use |
US20090060925A1 (en) * | 2004-08-03 | 2009-03-05 | The Trustees Of Columbia University In The City Of | Rage Fusion Proteins and Methods of Use |
US20090220484A1 (en) * | 2005-03-17 | 2009-09-03 | Ann Marie Schmidt | Rage/Diaphanous Interaction and Related Compositions and Methods |
US20100254983A1 (en) * | 2007-06-07 | 2010-10-07 | Ann Marie Schmidt | Uses of rage antagonists for treating obesity and related diseases |
Also Published As
Publication number | Publication date |
---|---|
US20020177550A1 (en) | 2002-11-28 |
US6465422B1 (en) | 2002-10-15 |
EP1071794A4 (en) | 2004-11-17 |
AU3495799A (en) | 1999-11-08 |
EP1071794A1 (en) | 2001-01-31 |
WO1999054485A1 (en) | 1999-10-28 |
CA2325573A1 (en) | 1999-10-28 |
JP2002512038A (en) | 2002-04-23 |
US7125675B2 (en) | 2006-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090191210A1 (en) | Method for inhibiting tumor invasion or spreading in a subject | |
JP4604227B2 (en) | Binding domains in Notch and Delta proteins | |
US6433149B1 (en) | Compounds and methods for inhibiting cancer metastasis | |
US6492325B1 (en) | Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease | |
CN101268102B (en) | Tissue inhibitor of metalloproteinases (TIMP) linked to glycosylphosphatidylinositol (GPI) -anchors for treatment of cancer and skin lesions | |
JP4219404B2 (en) | Novel agouti-related genes | |
EP1297013B1 (en) | Use of taci as an anti-tumor agent | |
EP1504764B1 (en) | Treatment of liver fibrosis with antibodies against alpha V beta 6 integrin | |
US20100062003A1 (en) | Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis | |
US8211864B2 (en) | Compositions and methods for the intracellular disruption of VEGF and VEGFR-2 by intraceptors | |
AU5350394A (en) | Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids | |
JP2012512185A (en) | Membrane type 1 matrix metalloprotein inhibitor and use thereof | |
US20150218247A1 (en) | Taci as an anti-tumor agent | |
KR100682666B1 (en) | Anti-angiogenic proteins and methods of use thereof | |
CA2329757C (en) | Use of .alpha.1.beta.1 integrin receptor inhibitors and tgf-.beta.1 inhibitors in the treatment of kidney disease | |
WO1999047152A2 (en) | Use of dipeptidyl peptidase (dpp4) of fibroblast activating protein alpha for suppressing the malignant phenotype of cancer cells | |
Panicot-Dubois et al. | Monoclonal antibody 16D10 to the C-terminal domain of the feto-acinar pancreatic protein binds to membrane of human pancreatic tumoral SOJ-6 cells and inhibits the growth of tumor xenografts | |
US20040106549A1 (en) | Anti-angiogenic proteins and methods of use thereof | |
WO1999045951A2 (en) | Thy-1 expression in angiogenesis | |
KR100574597B1 (en) | Use of ?1?1 integrin receptor inhibitors and tgf-?1 inhibitors in the treatment of kidney disease | |
JP2008500264A (en) | Methods and compositions for treating extracellular matrix disorders | |
JPH03505963A (en) | Common acute lymphoblastic leukemia antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE;ASSIGNOR:COLUMBIA UNIV NEW YORK MORNINGSIDE;REEL/FRAME:022322/0503 Effective date: 20090108 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR, MA Free format text: CONFIRMATORY LICENSE;ASSIGNOR:THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK;REEL/FRAME:042339/0747 Effective date: 20090108 |